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Functional,molecular and genetic neuroimaging has highlighted the existence of brain anomalies and neural vul-
nerability factors related to obesity and eating disorders such as binge eating or anorexia nervosa. In particular,
decreased basal metabolism in the prefrontal cortex and striatum as well as dopaminergic alterations have
been described in obese subjects, in parallel with increased activation of reward brain areas in response to palat-
able food cues. Elevated reward region responsivitymay trigger food craving and predict futureweight gain. This
opens the way to prevention studies using functional and molecular neuroimaging to perform early diagnostics
and to phenotype subjects at risk by exploring different neurobehavioral dimensions of the food choices andmo-
tivation processes. In the ﬁrst part of this review, advantages and limitations of neuroimaging techniques, such as
functional magnetic resonance imaging (fMRI), positron emission tomography (PET), single photon emission
computed tomography (SPECT), pharmacogenetic fMRI and functional near-infrared spectroscopy (fNIRS) will
be discussed in the context of recent work dealing with eating behavior, with a particular focus on obesity. In
the second part of the review, non-invasive strategies to modulate food-related brain processes and functions
will be presented. At the leading edge of non-invasive brain-based technologies is real-time fMRI (rtfMRI)
neurofeedback, which is a powerful tool to better understand the complexity of human brain–behavior relation-
ships. rtfMRI, alone or when combinedwith other techniques and tools such as EEG and cognitive therapy, could
be used to alter neural plasticity and learned behavior to optimize and/or restore healthy cognition and eating
behavior. Other promising non-invasive neuromodulation approaches being explored are repetitive transcranial
magnetic stimulation (rTMS) and transcranial direct-current stimulation (tDCS). Converging evidence points at
the value of these non-invasive neuromodulation strategies to study basicmechanisms underlying eating behav-
ior and to treat its disorders. Both of these approacheswill be compared in light of recentwork in this ﬁeld, while
addressing technical and practical questions. The third part of this review will be dedicated to invasive
neuromodulation strategies, such as vagus nerve stimulation (VNS) and deep brain stimulation (DBS). In combi-
nation with neuroimaging approaches, these techniques are promising experimental tools to unravel the
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intricate relationships between homeostatic and hedonic brain circuits. Their potential as additional therapeutic
tools to combat pharmacorefractory morbid obesity or acute eating disorders will be discussed, in terms of tech-
nical challenges, applicability and ethics. In a general discussion, wewill put the brain at the core of fundamental
research, prevention and therapy in the context of obesity and eating disorders. First, we will discuss the possi-
bility to identify new biological markers of brain functions. Second, wewill highlight the potential of neuroimag-
ing and neuromodulation in individualized medicine. Third, we will introduce the ethical questions that are
concomitant to the emergence of new neuromodulation therapies.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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1. Introduction
A recent study estimated the number of overweight adults in the
world as roughly 2.1 billion in 2013 (Ng et al., 2014). In the United
States alone, obese individuals have 42% higher health care costs than
those with healthy-weight (Finkelstein et al., 2009). Obesity is on the
rise, with severe obesity rising at a particularly alarming rate (Flegal
et al., 2010; Finkelstein et al., 2012). Because obesity is a multifactorial
conditionwith a complex etiology, and because success of interventions
is subject to a large interindividual variability, there is no panacea or
“one-ﬁt-all” treatment for obesity. Bariatric surgery (BS) is the treat-
ment of choice for severe obesity due to its effectiveness compared to
behavioral and pharmacological interventions (Buchwald and Oien,
2013). Its utility and success rate is widely accepted. However, 20–40%
of those who undergo BS fail to lose sufﬁcient weight (Christou et al.,
2006; Livhits et al., 2012) or regain signiﬁcant weight after treatment
(Magro et al., 2008; DiGiorgi et al., 2010; Adams et al., 2012), and can
experience a number of complications during and after surgery or med-
ical and psychiatric comorbidities (Shah et al., 2006; Karlsson et al.,
2007; DiGiorgi et al., 2010; Bolen et al., 2012; Chang et al., 2014). In ad-
dition to existing methods such as BS, which annually helps thousands
of people worldwide, there is a clear need for novel approaches to obe-
sity prevention and treatment, including the development of novel di-
agnostic and phenotyping methods, as well as adjunctive therapies
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that may lead to better treatment outcomes for patients who may
require invasive procedures such as BS. In comparison to the rising
obesity epidemic, eating disorders (ED) are scarcer but also certainly
underestimated and increasing at a startling state (Makino et al.,
2004). In the United States, up to 24 million people across all ages and
genders suffer from ED (anorexia— AN, bulimia— BN and binge eating
disorder— BED) (Renfrew Center Foundation for Eating Disorders, 2003),
and only 1 in 10 people with ED receives treatment (Noordenbox, 2002),
even though ED have the highest mortality rate of any mental illness
(Sullivan, 1995). Epidemiology of ED was described in details (including
risk factors, incidence, prevalence, and morbidity) in recent reviews
(see Smink et al., 2012; Mitchison and Hay, 2014).
In the ﬁght against obesity and eating disorders, improved knowl-
edge about the pathophysiological and neurobehavioral mechanisms
underlying these diseases is needed to better prevent risky behaviors,
diagnose and treat patients, and develop new therapies that are safer
and adjustable to each patient. As noted by Schmidt and Campbell
(2013), treatment of eating disorders cannot remain ‘brainless’, and
the same applies to obesity when we consider the growing amount of
literature highlighting the behavioral and brain changes/plasticity
induced by obesity (Wang et al., 2009b; Burger and Berner, 2014),
effective bariatric surgery (Geliebter, 2013; Scholtz et al., 2014), and
neuromodulatory interventions (McClelland et al., 2013a; Gorgulho
et al., 2014) in animal models and human subjects.
Although several excellent review papers on this subject exist (see
McClelland et al., 2013a; Sizonenko et al., 2013; Burger and Berner,
2014; Gorgulho et al., 2014), a comprehensive work comparing a large
spectrum of exploratory and therapeutic strategies using neuroimaging
and neuromodulation technologies, in terms of advantages and limita-
tions, degree of invasiveness, and applicability to individualized medi-
cine from prevention to treatment is missing and can help provide a
road map for future research and applications. Predictive and preven-
tion studies beneﬁting from neuroimaging are emerging thanks to the
characterization of neural vulnerability factors that increase risk for
weight gain and risky eating behaviors. The ﬁrst part of our review
will be dedicated to this question, aswell as to the role of functional, nu-
clear, and genetic neuroimaging in fundamental research and preven-
tion programs. A particular focus will be put on obesity, because it is
the number one concern, though references to speciﬁc ED will be in-
cluded when relevant. In this ﬁrst part we will also review for the ﬁrst
time the contribution of a less costly and more portable cortical func-
tional neuroimaging tool (i.e. fNIRS) in the context of research on eating
behavior. The second part of our reviewwill provide an overview of the
non-invasive neuromodulatory approaches to combat weight problems
and ED, including a presentation of real-time fMRI neurofeedback
coupled with cognitive therapy, aswell as a comparison between trans-
cranial magnetic stimulation (TMS) and transcranial direct current
stimulation (tDCS). The third section will be dedicated to more invasive
neuromodulatory approaches to modulate homeostatic and hedonic
mechanisms through the stimulation of the vagus nerve or deep-brain
structures. Finally, we will discuss all the data presented in the perspec-
tive of obesity/ED phenotyping and individualized medicine, while ad-
dressing the ethical questions raised by new therapeutic approaches
and their promise.
2.Utility of neuroimaging to investigate eatingbehavior andelucidate
risk and maintenance factors for weight gain and eating disorders:
towards new phenotyping and prevention strategies
2.1. Predicting future weight gain and maintenance on the basis of neural
responsivity and functioning
An improved understanding of the risk processes that give rise to ex-
cess weight gain should guide the design of more effective preventive
programs and treatments, which is vital because extant interventions,
with the possible exception of bariatric surgery, have limited efﬁcacy.
Theorists have focused on the reward circuitry because eating palatable
food increases activation in regions implicated in reward in both
humans and other animals, including the ventral and dorsal striatum,
midbrain, amygdala, and orbitofrontal cortex (OFC: Small et al., 2001;
Avena et al., 2006; Berridge, 2009; Stice et al., 2013) and causes dopa-
mine (DA) release in the dorsal striatum, with the amount released cor-
relating with meal pleasantness (Small et al., 2003) and caloric density
of the food (Ferreira et al., 2012) in humans. Both the orosensory prop-
erties of palatable food consumption (gustatory stimulation) and direct
intragastric infusion of high calorie food induce striatal DA release in re-
ward regions in human and animal studies (Avena et al., 2006; Tellez
et al., 2013).
2.1.1. Reward surfeit and incentive sensitization theories of obesity
The reward surfeitmodel holds that individuals with greater reward
region responsivity to food intake are at elevated risk for overeating
(Stice et al., 2008b). The incentive sensitization model posits that re-
peated intake of palatable foods results in an elevated responsivity of re-
ward regions to cues that are associated with palatable food intake via
conditioning, prompting elevated food intake when these cues are en-
countered (Berridge et al., 2010). According to animal studies, ﬁring of
striatal and ventral pallidum DA neurons initially occurs in response to
receipt of a novel palatable food, but after repeated pairings of palatable
food intake and cues that signal impending receipt of that food, DA neu-
rons begin ﬁring in response to reward-predictive cues and no longer
ﬁre in response to food receipt (Schultz et al., 1997; Tobler et al.,
2005). Elevated reward-related responses to food intake and cues puta-
tively override homeostatic processes of satiety, promoting excess
weight gain.
The present review focuses on prospective studies because cross-
sectional data cannot differentiate precursors from consequences of
overeating, with a focus on human studies unless otherwise indicated.
Hyper-responsivity of reward regions (striatum, amygdala, OFC) to pal-
atable food images (Demos et al., 2012), palatable food television com-
mercials (Yokum et al., 2014), geometric cues that signal impending
palatable food image presentation (Yokum et al., 2011), palatable food
odors that predict impending palatable food receipt (Chouinard-
Decorte et al., 2010; Sun et al., 2013), and pictorial cues that predict
impending palatable food receipt (Stice et al., 2015) predicted future
weight gain. Humans who show elevated dorsal striatum responsivity
to palatable food images show greater future weight gain, but only
if they are at genetic risk for higher DA signaling capacity due to
possessing an A2/A2 genotype of the TaqIA polymorphism or a 6-
repeat or shorter of the 48-base pair exon 3 variable number tandem re-
peat (VNTR) polymorphism of the DRD4 gene (Stice et al., 2010b),
which are both associated with greater DA signaling and reward region
responsivity (Jonsson et al., 1999; Bowirrat and Oscar-Berman, 2005).
The evidence from independent laboratories that elevated reward re-
gion responsivity to various food cues, including those that predict
impending palatable food receipt, predicted futureweight gain provides
behavioral support for the incentive sensitization theory.
Elevated midbrain, thalamus, hypothalamus, and ventral striatum
responsivity to milk shake taste also predicted future weight gain
(Geha et al., 2013; Sun et al., 2013). Further, individuals who show ele-
vated dorsal striatum responsivity to palatable food intake show greater
future weight gain, but only if they are at genetic risk for elevated DA
signaling capacity by virtue of possessing an A2/A2 genotype of the
TaqIA polymorphism (Stice et al., 2008a; Stice et al., 2015). The evidence
that individualswho showelevated reward region responsivity to palat-
able food intake are more likely to enter a prolonged period of positive
energy balance and gain weight provides behavioral data in support of
the reward surfeit theory.
Although extant data provide support for both the incentive sensiti-
zation and reward surfeit theories of obesity,which are notmutually ex-
clusive, future studies should simultaneously examine individual
differences in neural response to palatable food taste, cues that signal
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impending palatable food taste, and palatable food images to provide a
more comprehensive investigation of neural vulnerability factors that
predict future weight gain. Results imply that prevention programs
that reduce habitual intake of high-calorie foods should attenuate the
conditioning process that eventually leads to elevated reward region
responsivity to food cues, which may reduce future weight gain. Yet,
the fact that behavioral weight loss programs typically result in a tran-
sient reduction of high-calorie food intake, but do not produce sustained
weight loss implies that it is very difﬁcult to reduce reward region
hyper-responsivity to food cues once it has emerged. An uncontrolled
study suggested that humans who have been able to sustain their
weight loss over long periods of time carefully limit intake of high-
calorie foods, exercise daily, and monitor their weight (Wing and
Phelan, 2005). These observations imply that it would be useful to test
whether interventions that increase executive control, either by direct
modiﬁcation of brain-behavior function or indirectly by modiﬁcation
of the environment (which could offset the risk from elevated reward
region responsivity) result in more lasting weight loss.
2.1.2. Reward deﬁcit theory of obesity
The reward deﬁcit model of obesity posits that individuals with
lower sensitivity of DA-based reward regions overeat to compensate
for this deﬁciency (Wang et al., 2002). There have only been a few pro-
spective fMRI studies that could have potentially determined whether
reduced reward region responsivity preceded weight gain, and there
have not been any prospective studies that assessed with DA function-
ing (e.g. assessed with PET) predicted future weight change. Out of
the six prospective studies that examined the relation of BOLD response
to palatable food images, cues that signal impending palatable food re-
ceipt, and actual palatable food receipt to future weight gain reviewed
above (Chouinard-Decorte et al., 2010; Yokum et al., 2011; Demos
et al., 2012; Geha et al., 2013; Yokum et al., 2014; Stice et al., 2015),
none found a relation between reduced reward region responsivity to
these food stimuli and greater future weight gain. Interestingly, howev-
er, a prospective study found that young adults who showed lower re-
cruitment of striatal regions in response to milk shake receipt (Stice
et al., 2008b, 2015) and palatable food images (Stice et al., 2010b)
showed greater future weight gain if they had a genetic propensity for
reduced DA signaling capacity. The interactive effects imply that there
may be qualitatively distinct reward surfeit and reward deﬁcit path-
ways to obesity, which should be investigated further.
Obese versus lean adults have shown lower striatal DA D2 receptor
availability (Volkow et al., 2008; de Weijer et al., 2011; Kessler et al.,
2014) and less striatal responsivity to high-calorie beverage taste
(Stice et al., 2008b). Interestingly, Guo et al. (2014) also suggested
that obese people have alterations in the DA neurocircuitry thatmay in-
crease their susceptibility to opportunistic overeatingwhile at the same
time making food intake less rewarding, less goal directed and more
habitual. Whether the observed neurocircuitry alterations pre-exist or
occur as a result of obesity development is still controversial, but consid-
erable evidence suggests that overeating contributes to a down-
regulation of the DA-based reward circuitry. Lean younger subjects at
risk for future obesity due to parental obesity show hyper- rather than
hypo-responsivity of reward regions to palatable food receipt (Stice
et al., 2011).Womenwhogainedweight over a 6-month period showed
a reduction in striatal responsivity to palatable food receipt relative to
baseline and to women who remained weight stable (Stice et al.,
2010a). Rats randomized to overeating conditions that result in weight
gain versus control conditions show a down-regulation of post-synaptic
D2 receptors, and reduced D2 sensitivity, extracellular DA levels in the
nucleus accumbens and DA turnover, and lower sensitivity of DA re-
ward circuitry (Kelley et al., 2003; Davis et al., 2008; Geiger et al.,
2009; Johnson and Kenny, 2010). Minipigs randomized to a weight
gain intervention versus a stable weight condition showed reduced
prefrontal cortex, midbrain and nucleus accumbens resting activity
(Val-Laillet et al., 2011). The reduced DA signaling capacity appears to
occur because habitual intake of high-fat diets causes decreased synthe-
sis of oleoylethanolamine, a gastrointestinal lipid messenger (Tellez
et al., 2013). Interestingly, peoplewho report elevated intake of a partic-
ular food show reduced striatal response during intake of that food, in-
dependent of BMI (Burger and Stice, 2012; Green and Murphy, 2012;
Rudenga and Small, 2012).
Geiger et al. (2009) hypothesized that diet-induced down-regulation
of the DA circuitry may prompt overeating to increase DA signaling. Yet,
mice in which reduced striatal DA signaling from food intake was exper-
imentally induced through chronic intragastric infusion of fat worked less
for acute intragastric infusion of fat and consumed less rat chow ad lib
than control mice (Tellez et al., 2013). Further, genetically engineered
DA-deﬁcient mice are unable to sustain appropriate levels of feeding
(Sotak et al., 2005). These data seem incompatible with the notion that
an induced down-regulation of DA reward circuitry leads to compensato-
ry overeating. The Tellez et al. (2013) study also provided further evi-
dence that intake of fat can result in reduced DA response to food
intake, independent of weight gain per se.
2.1.3. Inhibitory control
Vulnerabilities in reward sensitivity, habit, and inhibitory control
appear to interact to produce prolonged hyperphagia of highly palatable
foods leading to the development and maintenance of obesity
(Appelhans et al., 2011). By extension, lower activation of prefrontal-
parietal brain regions implicated in inhibitory control, may lead to
greater sensitivity to the rewarding effects of highly palatable foods
and greater susceptibility to the pervasive temptation of appetizing
foods in our environment, which increases overeating in the absence
of meeting homeostatic energy needs (Nederkoorn et al., 2006). In
fact, this pattern of food intake behavior appears to occur with only a
limited role for homeostatic input inmodulating obesogenic food intake
behavior (Hall et al., 2014). Inefﬁcient or underdeveloped inhibitory
control function may increase the risk for obesity in early childhood at
a time when rapid development is occurring in subcortical and
prefrontal–parietal brain systems that support reward and inhibitory
control functions (see Reinert et al., 2013; Miller et al., 2015 for re-
cent reviews). In addition, obesity-related alterations in adipokines,
inﬂammatory cytokines, and gut hormones may lead to further dis-
ruption in neurodevelopment, especially in reward and inhibitory
control functions, which may increase the risk for poor academic perfor-
mance and even dementia risk in later life (Miller et al., 2015). For exam-
ple, obese versus lean teens showed less activation of prefrontal regions
(dorsolateral prefrontal cortex [dlPFC], ventral lateral prefrontal cortex
[vlPFC]) when trying to inhibit responses to high-calorie food images
and behavioral evidence of reduced inhibitory control (Batterink et al.,
2010) and adults who had greater dlPFC activation when instructed to
“resist craving”while viewing food images had better weight loss success
following gastric bypass surgery (Goldman et al., 2013). Another study
found that participantswho showed less recruitment of inhibitory control
regions (inferior, middle, and superior frontal gyri) during difﬁcult versus
easy choices on a delay discounting task showed elevated future weight
gain (Kishinevsky et al., 2012; r=0.71); however, individual differences
in delay discounting behavior did not explain weight outcomes (Stoeckel
et al., 2013b). These results convergewith evidence that obese versus lean
adults showed reduced gray mater volume in the prefrontal cortex
(Pannacciulli et al., 2006), a region that modulates inhibitory control,
andwith amarginal trend for reduced graymatter volume in the prefron-
tal cortex to predict weight gain over 1-year follow-up (Yokum et al.,
2011). Interestingly, obese versus lean humans also showed less recruit-
ment of inhibitory regions (ventral medial prefrontal cortex [vmPFC]) in
response to high-calorie food images (Silvers et al., 2014) and high-
calorie food TV commercials (Gearhardt et al., 2014). Further, lower
dlPFC response to high-calorie food images predicted greater ad lib food
intake over the next 3 days (Cornier et al., 2010). These ﬁndings are note-
worthy because all but the results from the Batterink, Kishinevsky, and
Stoeckel studies emerged in paradigms lacking a behavioral response
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component. In some instances (Kishinevsky et al., 2012; Stoeckel et al.,
2013b), the neuroimaging data were a better predictor of weight out-
comes than the behavioral measure. This example highlights the future
potential for “neuromarkers” to improve outcome prediction and individ-
ualize intervention strategies to improveweight outcomes (Gabrieli et al.,
2015). Finally, it may also be possible to directly target and normalize
these brain systems using several of the neuromodulatory tools and tech-
niques described throughout this article, such as transcranial stimulation,
to enhance treatment outcomes (Alonso-Alonso and Pascual-Leone,
2007).
2.1.4. Theoretical implications and future research directions
Thus, most prospective and experimental studies have not provided
support for the reward deﬁcit theory of obesity, and whereas available
data suggest that the reduced DA signaling capacity of the reward cir-
cuitrymay largely result from overeating, extent data provide little sup-
port for the notion that this contributes to compensatory overeating.
Yet, there is emerging evidence that there may be qualitatively distinct
reward surfeit and reward deﬁcit pathways to obesity that are based on
individual differences in genes that affect DA signaling and reward re-
gion responsivity to palatable food receipt, implying that it might be
useful to reﬁne our working model regarding neural vulnerability
factors that contribute to obesity. According to what might be referred
to as the dual pathway model of obesity, we posit that individuals in
the reward surfeit pathway initially show hyper-responsivity of reward,
gustatory, and oral somatosensory regions to palatable food intake,
which increases habitual intake of energy dense foods. The reward sur-
feit pathwaymight bemore likely for those at genetic risk for greater DA
signaling capacity. Habitual intake of palatable foods theoretically leads
to the development of hyper-responsivity of attention and reward valu-
ation regions to cues that predict food reward through conditioning
(Berridge, 2009), which maintains overeating because exposure to
ubiquitous food cues results in craving that prompts eating. Data sug-
gest that the hyper-responsivity of reward regions to palatable food in-
take contributes to more pronounced cue-reward learning, which
increases risk for future weight gain (Burger and Stice, 2014). We fur-
ther submit that overeating results in a down-regulation of DA-based
reward regions, producing a blunted striatal response to food intake
that emerges with obesity, but that this may not contribute to further
escalation in eating. We also theorize deﬁcits in inhibitory control in-
crease the risk for overeating, and further that overeating leads to a sub-
sequent reduction in inhibitory response to food stimuli, which may
also contribute to future escalation in overeating. This prediction is
based on evidence that individuals exhibit greater inhibitory control
deﬁcits in response to frequently versus infrequently experienced re-
wards; obese versus lean individuals show a greater immediate reward
bias to food stimuli but not monetary reward (Rasmussen et al., 2010).
In contrast, individuals in the reward deﬁcit pathway, which may be
more likely for those with a genetic propensity for lower DA-signaling
capacity, might consume more calories per eating episode because the
weaker DA-signaling may attenuate feelings of satiety, as reward re-
gions project to the hypothalamus. It is possible that the weaker DA-
signaling of reward regions attenuates the effects of gut peptides that
relay satiety. It is also possible that the lower DA signaling and reward
region responsivity operates through a completely different process,
such as by reducing physical activity because these individuals might
ﬁnd exercise less rewarding, contributing to a positive energy balance.
More broadly, data imply that too much or too little reward circuitry
responsivity, which is referred to as the Goldilocks Principle, serves to
disrupt homeostatic processes that have evolved to promote sufﬁcient,
but not excessive caloric intake. This notion would be consistent with
an allostatic load model.
With regard to future research, additional large prospective brain
imaging studies should seek to identify neural vulnerability factors
that predict future weight gain. Second, environmental, social, and bio-
logical factors, including genotypes, that moderate the effects of these
vulnerability factors on future weight gain should be examined in
more detail. Third, additional prospective repeated-measures studies
should attempt to capture the plasticity of reward region responsivity
to food images/cues and food receipt, which appears to results from
overeating. Randomized controlled experiments could be used to ad-
dress these research questions, allowing much stronger inferences re-
garding these etiologic processes. It will also be important to expand
research into other relevant neuropsychological functions (e.g. motiva-
tion, workingmemory, multisensory processing and integration, execu-
tive function), the neural systems that mediate these functions, their
interactionwith reward andhomeostatic (i.e. hypothalamic, brainstem)
brain systems, and how dysfunction in these neural systems and cogni-
tive functionsmay impact reward and homeostatic functions in order to
have a more uniﬁed brain–behavior model of food intake behavior
(Berthoud, 2012; Hall et al., 2014). For example, inhibitory control and
the fronto-parietal brain systems that mediate this function have been
studied; however, there are other aspects of executive function (e.g.
mental set shifting, information updating and monitoring; Miyake
et al., 2000) that are mediated by dissociable, but overlapping regions
of the fronto-parietal “executive” network and are understudied in the
context of their relationship to food intake behavior. Finally, investiga-
tors should continue to translate ﬁndings from brain imaging studies
into more effective obesity prevention and treatment interventions.
2.2. Dopaminergic imaging
As reviewed above, dopamine (DA) plays an important role in eating
behavior. Understanding the neurocognitive mechanisms by which DA
inﬂuences eating behavior is crucial for prediction, prevention and
(pharmacological) treatment of obesity. To infer the involvement of
the dopaminergic system, it is important to actually measure DA pro-
cessing. Findings of increasedmetabolismor bloodﬂow in a dopaminer-
gic target region do not necessarily imply that DA is directly involved.
For example, activation in the striatum could reﬂect opioid modulation
of hedonic ‘liking’ instead of dopaminergic modulation of ‘wanting’
(Berridge, 2007). Here, wewill go intomore detail about results of stud-
ies directly investigating DA.
2.2.1. Nuclear tomographic imaging
Nuclear imaging techniques such as positron emission tomography
(PET) and single photon emission computed tomography (SPECT) use
radioactive tracers and detection of gamma rays to image tissue concen-
trations ofmolecules of interest (e.g. DA receptors). PET and SPECT have
a very low temporal resolution (tens of seconds tominutes), usually re-
quiring one imaging session for one data point, limiting the kind of re-
search questions that can be targeted with these methods.
Table 1 provides an overview of dopaminergic PET and SPECT stud-
ies that have assessed differences as a function of BMI in humans. In line
with a downregulation of dopamine signaling with obesity is the rela-
tion between lower dopamine synthesis capacity in the dorsal striatum
and an elevatedBMI (Wilcox et al., 2010;Wallace et al., 2014) and lower
striatal DA D2/D3 receptor binding in obese versus lean individuals
(Wang et al., 2001; Haltia et al., 2007; Volkow et al., 2008; de Weijer
et al., 2011; Kessler et al., 2014; van de Giessen et al., 2014). However,
others have foundpositive associations between striatal D2/D3 receptor
binding and BMI (Dunn et al., 2012; Caravaggio et al., 2015), or no asso-
ciation (Eisenstein et al., 2013). From the above-mentioned studies it is
also unclear whether differences in DA processing reﬂect a cause or a
consequence of an increased BMI. Some have touched upon this ques-
tion by assessing changes in DA D2/D3 receptor binding after bariatric
surgery and signiﬁcant weight loss. While one study found increases
and the other found decreases in receptor binding after surgery (Dunn
et al., 2010; Steele et al., 2010), a study with a larger sample did not
ﬁnd any signiﬁcant changes (de Weijer et al., 2014).
Another way to investigate the involvement of DA in obesity is to as-
sess changes in extracellular DA levels induced by a psychostimulant or
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Table 1
Summary of studies using SPECT or PET for dopaminergic imaging in lean, overweight or obese human subjects.
Subjects, status Radioligand Marker for Challenge Main ﬁndings References
SPECT studies
n = 15 obese (BMI 43 ± 5) vs.
n = 15 non-obese (BMI 22 ± 2)
[123I] iodobenzamide (IBZM) DA D2/3R 2 sessionsa: after amphetamine
vs. baseline
Obese individuals had lower striatal DA D2/3R binding than
controls at baseline; increases in extracellular dopamine were
correlated with enhanced trait food craving in obese individuals
van de Giessen
et al. (2014)
n = 19 bariatric surgery patients
(BMI 46 ± 6 before and 41 ± 6
after)
[123I] iodobenzamide (IBZM) DA D2/3R None No signiﬁcant changes in striatal DA D2/3R binding before vs.
6 weeks after bariatric surgery were found; and no correlation
with BMI before or after surgery
de Weijer et al.
(2014)
n = 123 (BMI 18–41) [(123)I]FP-CIT DAT None No association between striatal DAT binding and BMI was found van de Giessen
et al. (2013)
n = 33 (BMI 21–50) [123I] PE2I DAT None No association between striatal DAT binding and BMI was found Thomsen et al.
(2013)
n = 15 obese (BMI 47 ± 7) vs.
n = 15 non-obese (BMI 22 ± 2)
[123I] iodobenzamide DA D2/3R None Obese individuals had lower striatal DA D2/3R binding than
controls
de Weijer et al.
(2011)
n = 50 (BMI 19–31) [99mTc]-TRODAT-1 DAT None Lower DAT binding in the striatum was correlated with a higher
BMI
Chen et al. (2008)
PET studies
n = 13 obese (BMI 37–49)
n = 24 non-obese (BMI 23 ± 3)
[11C] carfentanil
[11C] raclopride
μ-Opioid R
DA D2/3R
None No difference in D2/D3R availability between obese and
non-obese women, but signiﬁcantly reduced μ-opioid R
availability in obese women
Karlsson et al.
(2015)
n = 19 (BMI 21–35) [11C] raclopride DA D2/3R 2 sessionsa: glucose (caloric) vs.
sucralose (non-caloric)
Calorie-induced increases in extracellular dopamine in ventral
striatum were correlated with a lower BMI
Wang et al. (2014)
n = 16 (BMI 20–33) 6-[18F]-Fluoro-L-m-Tyrosine (FMT) AADC, DA synthesis None Lower dopamine synthesis in caudate nucleus was correlated
with 1) greater BMI and 2) greater preference for perceived
“healthy”, but not actual healthy, foods (independent of BMI)
Wallace et al.
(2014)
n = 33 (n = 16) (BMI 19–35) [18F] fallypride DA D2/3R 2 sessions (n = 16)a: after
amphetamine vs. baseline
Lower DA D2/3R binding in caudate and amygdala was correlated
with a higher BMI at baseline; amphetamine-induced increases in
extracellular dopamine in putamen and substantia nigra were
correlated with a higher BMI
Kessler et al. (2014)
n = 15 obese (BMI 33 − 47) vs.
n = 15 non-obese (BMI 19–28)
(N-[(11)C] methyl) benperidol
([(11) C] NMB)
DA D2R-speciﬁc,
non-displaceable
None No association between striatal DA D2 binding and BMI was
found
Eisenstein et al.
(2013)
n = 26 vs. n = 35 (BMI 19–28) [11C]-(+)-PHNO vs. [11C]
raclopride
DA D2/3R (agonist vs.
antagonist)
None Higher DA D2/3R binding in ventral striatum, as measured with
[11C]-(+)-PHNO, was correlated with a higher BMI
Caravaggio et al.
(2015)
n = 14 obese (BMI 40 ± 5) vs.
n = 8 non-obese (BMI 23 ± 2)
[18F] fallypride DA D2/3R None Lower DA D2/3R binding in caudate was correlated with a lower
BMI
Dunn et al. (2012)
n = 15 (BMI 25) 6-[18F]-Fluoro-L-m-Tyrosine (FMT) AADC, DA synthesis None Lower DA synthesis capacity in the dorsal striatum was
correlated with a higher BMI (caudate) and increased weight loss
attempts (putamen)
Wilcox et al. (2010)
n = 5 bariatric surgery patients
(45 ± 6 before and 38 ± 7 after)
[11C] raclopride DA D2/3R None Four out of ﬁve patients showed an increase in DA D2/3R binding
in the striatum 6 weeks after bariatric surgery
Steele et al. (2010)
n = 5 bariatric surgery patients (BMI
43 ± 3 before and 38 ± 3 after)
[18F] fallypride DA D2/3R None DA D2/3R binding in striatum, (hypo) thalamus, substantia nigra
(corrected for multiple comparisons) and amygdala decreased
7 weeks after bariatric surgery
Dunn et al. (2010)
n = 10 obese (BMI 51 ± 5) vs.
n = 12 non-obese (BMI 25 ± 3)
[11C] raclopride and [18F]
ﬂudeoxyglucose (FDG)
DA D2/3R; glucose None In obese individuals striatal D2/3R binding was lower than
controls and was positively correlated with glucose metabolism
in frontal and somatosensory cortices
Volkow et al.
(2008)
n = 12 obese (BMI 33 ± 5) vs.
n = 12 non-obese (BMI 22 ± 1)
[11C] raclopride DA D2/3R 2 sessionsa:after i.v. glucose vs.
after i.v. placebo
Obese individuals had lower striatal DA D2/3R binding than
controls; glucose increased extracellular striatal dopamine in
men and reduced it in women
Haltia et al. (2007)
n = 10 obese (BMI 42–60) vs.
n = 10 non-obese (BMI 21–28)
[11C] raclopride DA D2/3R None Obese individuals had lower striatal DA D2/3R binding than
controls; lower striatal DA D2/3R binding was correlated with a
higher BMI in obese individuals
Wang et al. (2001)
BMI: body mass index (kg/m2); “x–x” reﬂects the range, and“x ± x” reﬂects the average ± standard deviation; PET: positron emission tomography; DA: dopamine; D2/3R: D2/D3 receptor;
a Increases in extracellular dopamine were observed as reductions in binding potential; i.v.: intravenous; SPECT: single photon emission tomography; DAT: dopamine transporter; AADC: aromatic l-amino acid decarboxylase.
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a food challenge (see Table 1). In such challenge studies, lower receptor
binding is interpreted as greater release of endogenous DA leading to
greater competition with the radioligand at the receptors. Challenge
studies have observed that food- or psychostimulant-induced increases
in extracellular striatal DA are associatedwith a lower BMI (Wang et al.,
2014), a higher BMI (Kessler et al., 2014), or have found no differences
between BMI groups (Haltia et al., 2007).
In sum, ﬁndings from nuclear imaging studies investigating differ-
ences in the striatal DA system as a function of BMI are very inconsis-
tent. In an attempt to converge on one theory of dopaminergic hypo-
activation in obesity, different authors have used different explanations
for their results. For example, DA D2/D3 receptor binding has been
interpreted to reﬂect DA receptor availability (e.g. Wang et al., 2001;
Haltia et al., 2007; Volkow et al., 2008; de Weijer et al., 2011; van de
Giessen et al., 2014), DA receptor afﬁnity (Caravaggio et al., 2015), or
competition with endogenous DA (Dunn et al., 2010; Dunn et al.,
2012). Based on the data, it is often unclear whether such differences
in interpretation are valid. In addition, a very recent study by Karlsson
and colleagues showed a signiﬁcant reduced μ-opioid receptor availabil-
ity in obese compared to normal-weight women, without changes in
D2-receptor availability, which might be an additional channel that
might explain the inconsistent ﬁndings in a lot of other studies
(Karlsson et al., 2015).
2.2.2. Genetic fMRI
By investigating the effects of common variations in DA genes the
role of predisposed vulnerability can be determined. To date, there
have only been a few studies that have combined genetics with neuro-
imaging in thedomain of food reward.Most of themare functionalmag-
netic resonance imaging (fMRI) studies.
Most genetic fMRI studies investigating food reward have taken into
account a common variation (i.e. polymorphism) referred to as TaqIA, of
which the A1 allele has been positively associated with BMI in several
early genetic studies (Noble et al., 1994; Jenkinson et al., 2000; Spitz
et al., 2000; Thomas et al., 2001; Southon et al., 2003). The TaqIA poly-
morphism is located in the ANKK1 gene, ~10 kb downstream of the
DRD2 gene (Neville et al., 2004). A1-allele carriers of the TaqIA poly-
morphism show reduced striatal D2R expression (Laruelle et al., 1998;
Pohjalainen et al., 1998; Jonsson et al., 1999). Genetic fMRI studies
have demonstrated that A1-carriers show decreased blood-oxygen-
level-dependent (BOLD) responses in DA-rich regions in the brain (dor-
sal striatum,midbrain, thalamus, orbitofrontal cortex)when consuming
a milk shake versus a tasteless solution relative to non-carriers (Stice
et al., 2008a; Felsted et al., 2010). Importantly, these decreased re-
sponses for food reward consumption, as well as for imagined food in-
take, predicted future weight gain in the A1 risk allele carriers (Stice
et al., 2008a; Stice et al., 2010b). This is in line with the idea that DA
modulates the blunted response to food reward in obesity. In contrast,
when anticipating a milk shake versus a tasteless solution, A1-carriers
have demonstrated increased BOLD responses in the midbrain (Stice
et al., 2012). Amultilocus composite score of dopaminergic genotypes—
including ANKK1 and four others— did not predict decreased striatal re-
sponses for the consumption of food reward, but only for the receipt of
monetary reward (Stice et al., 2012).
Thus, genetic fMRI studies suggest that individual differences in do-
paminergic genes play a role in brain responses to food reward, but their
effects are not always replicated and seem to dependon the anticipation
or the consumption of food reward.
2.2.3. Future directions for dopaminergic imaging
Together, SPECT, PET, and genetic fMRI studies suggest that brain DA
is involved in obesity. However, these neuroimaging ﬁndings are not
easily interpreted as a simple hypo- or hyper-activation of the DA sys-
tem in obesity. Moreover, there is an abundance of non-replications
and null ﬁndings, possibly due to small sample sizes. In order to use do-
paminergic imaging as a phenotyping method indicating vulnerability
for obesity or for prediction of treatment efﬁcacy, reliability should be
increased. Genetic pathway analyses (e.g. Bralten et al., 2013) or ge-
nome wide association studies (e.g. El-Sayed Moustafa and Froguel,
2013; Stergiakouli et al., 2014) might be more sensitive and speciﬁc in
revealing DA3s role in obesity. In the context of personalized medicine,
DA genetic fMRI studies could be combined with pharmacology (see
Kirsch et al., 2006; Cohen et al., 2007; Aarts et al., 2015) to reveal the
mechanisms of anti-obesity drugs as well as individual differences in
treatment response.
Another reason for the observed inconsistencies might be that obe-
sity (i.e. BMI) is too complex and unspeciﬁc as a phenotype (see also
Ziauddeen et al., 2012), which is also evident from the fact that studies
using polygenic risk scores have only obtained small associations with
obesity phenotypes (e.g. Domingue et al., 2014). Neuroimaging studies
might more clearly reveal dopaminergic effects when using cognitive
paradigms that manipulate food motivation (i.e. effort provision) or
the learning of cue-reward associations, as striatal DA is well known
for its role in these processes (Robbins and Everitt, 1992; Schultz et al.,
1997; Berridge and Robinson, 1998). Assessing task-related responses,
however, is a challenge during PET and SPECT due to their low temporal
resolution. Nevertheless, PET/SPECT measures could be related to off-
line task behavior (see, e.g. Wallace et al., 2014). Moreover, combina-
tions of imaging modalities such as PET and fMRI holds a strong poten-
tial for future studies (see, e.g. Sander et al., 2013 in non-human
primates),making optimal use of the speciﬁcity of PET and the temporal
and spatial resolution of fMRI.
2.3. The contribution of functional near-infrared spectroscopy (fNIRS)
Unlike the other neuroimaging techniques, such as PET and fMRI,
fNIRS does not require subjects to be in a supine position and does not
strictly restrict head movements, thus allowing to adopt a wide range
of experimental tasks suitable for properly investigating eating disor-
ders and food intake/stimuli. In addition, fNIRS uses a relatively low
cost instrumentation (with a sampling time in the order of the ms and
a spatial resolution of up to about 1 cm). On the other hand, although
EEG is a useful electrophysiological technique, its very low spatial reso-
lution makes it difﬁcult to precisely identify the activated areas of the
brain, limiting its application to speciﬁc research questions related to
eating disorders (Jauregui-Lobera, 2012). Recently, to deal with this
problem EEG has been combined successfully with fMRI to overcome
the spatial limitations of EEG and the temporal limitations of fMRI,
using their complementary features (Jorge et al., 2014). The parallel or
sequential use of EEG and fMRI in food related studies may provide ad-
ditional insights into neural processing cascades. However, combined
EEG–fMRI food related studies have not been reported yet. In conclu-
sion, all the above mentioned advantages of using fNIRS and EEG offer
the great promise to explore taste-related higher cognitive brain
functions, which require tasks involving even the ingestion of food/
beverages under more natural situations.
2.3.1. Brief overview of the principles, advantages and limitations of fNIRS
The principles, advantages, and limitations of fNIRS or optical topogra-
phy or near-infrared (NIR) imaging have been summarized in recent
reviews (Hoshi, 2011; Cutini et al., 2012; Ferrari and Quaresima, 2012;
Scholkmann et al., 2014). fNIRS is a non-invasive vascular-based
neuroimaging technology that measures concentration changes of
oxygenated-hemoglobin (O2Hb) and deoxygenated-hemoglobin (HHb)
in cortical microcirculation blood vessels. fNIRS relies on neurovascular
coupling to infer changes in neural activity that is mirrored by changes
in blood oxygenation in the region of the activated cortical area (i.e. the
increase in O2Hb and the decrease in HHb). Unlike the BOLD signal of
fMRI, which is gathered from the paramagnetic properties of HHb, the
fNIRS signal is based on the changes in the intrinsic optical absorption
of both HHb and O2Hb (Steinbrink et al., 2006). fNIRS systems vary in
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Table 2
fNIRS cognitive processing studies in patients with eating disorders, as well as healthy subjects/patients upon food intake or food stimuli.
Food stimulus or food intake Task (s) Subjects, status Age
(years; mean ± SD)
Range (years) Device Ch Cortical
area
Main ﬁnding References
Frontal cortex reactivity in patients with eating disorders
n.u. VFT; RPST 14, HC; 10, AN;
14, BN
24.1 ± 3.0; 26.1 ± 7.1 n.a. D8 2 PFC Higher dlPFC activation in BN Sutoh et al. (2013)
n.u. VFT; control: FOT 12, HC; 16, AN 14.3 ± 1.3; 14.2 ± 1.3 n.a. D4 24 PFC VFT: AN poor PFC activation; FOT: similar
PFC activation in AN and HC
Nagamitsu et al. (2011)
n.u. VFT 27, HC; 27, ED 22.4 ± 2.0; 23.5 ± 5.2 n.a. D4 52 FT ED: bilateral OFC and right FT smaller
activation
Suda et al. (2010)
n.u. VFT 11, HC; 11, ED 26.9 ± 2.2; 21.2 ± 6.0 18–32; 14–38 D3 24 PFC Lower PFC activation in ED Uehara et al. (2007)
Effects of food taste
Sweet taste: sucrose (10%); sour taste:
citric acid (10%)
Pleasant/unpleasant
tasting task
16, HC 26.3 ± 5.5 n.a. D10 16 PFC Bilateral FP and dlPFC deactivation to
both tastes; higher right PFC activation
with citric acid
Hu et al. (2014)
Sweet snacks Taste stimulation 6, HC 21.5 ± 1.3 19–27 D5 44 PFC Bilateral primary taste area, inferior
frontal gyrus, and dlPFC activation
Ono (2012)
Different liquid taste-stimuli Encoding and retrieval of
taste memory
28, HC 32 ± 7 21–49 D12 23 PFC Bilateral FP and right DLPFC larger
activation in retrieval
Okamoto et al. (2011)
Bitter: 6-n-propylthiouracil Tasting task 48, HC n.a. 24–40 D3 24 dlPFC,
vlPFC
dlPFC and vlPFC activation Bembich et al. (2010)
Different sugar based taste-stimuli;
control: VFT, TTT
Taste stimulation 19, HC 32.1 ± 6.9 23–44 D12 17 PFC vlPFC is involved in the act of tasting. Okamoto et al. (2009)
7 green tea samples Sensory evaluation 12, HC n.a. 23–42 D12 14 lPFC Left lPFC and right inferior frontal gyrus
activation
Okamoto et al. (2006a)
Different liquid taste-stimuli; control:
TTT
Taste encoding task 18, HC n.a. 25–44 D12 17 PFC vlPFC activation Okamoto et al. (2006b)
Effects of food ﬂavor
Sweet taste/sweet taste-lemon odor/no
taste-odor gums
Chewing test 25, HC 27.8 ± 2.8 n.a. D8 2 PFC Combination of taste/odor increases PFC
activation
Hasegawa et al. (2013)
Ethylmaltol-ﬂavored 4% sucrose solution Sensory evaluation tasks 7, HC 31.4 ± 4.5 n.a. D4 52 PFC Ethylmaltol enhances the TC activation
when combined with a sweet taste
Saito-Iizumi et al.
(2013)
Flavored and odorless broth stimuli Sensory evaluation task 10, HC 30.5 ± 4.6 n.a. D4 52 FP, FT Bilateral TC activation upon ﬂavored
broth taste
Matsumoto et al.
(2012)
Effects of odor food components
Irritating and hedonic odors Olfactory stimulation test 11, HC; 12, MCS n.a. n.a. D13 42 PFC PFC activation in MCS and controls Azuma et al. (2013)
Isovaleric acid (sweet smell) Olfactory stimulation test 19, HC; 36, D 42.5; 60.9 22–67; 37–81 D3 22 PFC Activation of the lower part of the PFC in
HC; no activation in D subjects
Kobayashi et al. (2012)
2-Phenyl ethanol and citral Olfactory stimulation test 14, HC 19.6 18–23 D1 2 OFC Left OFC activation; right OFC activation
upon odor recognition
Kokan et al. (2011)
Linalool (mixed olfactory stimulant) Olfactory stimulation test 22, HC; 27, ADHD 12.4 ± 1.6; 12.7 ± 1.4 n.a. D4 48 PFC Higher TC activation in ADHD without
methylphenidate therapy
Schecklmann et al.
(2011a)
2-Phenyl ethanol; linalool (mixed
olfactory stimulant)
Olfactory stimulation test 29, HC; 29, ADHD 27.8 ± 4.1; 28.2 ± 4.5 n.a. D4 44 PFC Methylphenidate normalizes the ADHD
TC activation
Schecklmann et al.
(2011b)
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Isovaleric acid (sweet smell) Olfactory stimulation test 8, HC; 5, D 28.9; 46.9 22–39; 17–69 D3 22 PFC Activation of the lower part of the PFC in
HC; no activation in D subjects
Kobayashi et al. (2009)
Isovaleric acid (sweet smell) Olfactory stimulation test 8, HC 28.9 22–39 D3 22 PFC Activation of the lower part of the PFC Kobayashi et al. (2007)
Pleasant: vanilla essence, strawberry
essence; unpleasant: scatol
Olfactory stimulation test 13, HC 23–31 D9 2 PFC PFC activation related to odor strength Harada et al. (2006)
Pleasant: vanilla substance (1%) Olfactory stimulation test 8, HC; 13, MA 66; 66 56–79; 56–72 D9 2 TC Bilateral TC activation only in HC Fladby et al. (2004)
2-Phenyl ethanol, isovaleric acid Olfactory stimulation test 12, HC 32.6 ± 14.9 n.a. D15 2 TC Bilateral TC activation (right TC higher
activation)
Ishimaru et al. (2004)
Effects of nutrition/food components
7-day essence of chicken/placebo
supplementation
Working memory and
reaction tasks
12, HC 62.3 ± 2.5 60–68 D4 24 PFC dlPFC activation only with chicken
essence upon working memory task
Konagai et al. (2013a)
12-week krill/sardine oil
supplementation
Working memory and
calculation tasks
45, HC 67.1 ± 3.4 n.a. D4 24 PFC Greater dlPFC activation with krill oil Konagai et al. (2013b)
Glucose drink (50 mg) Divided attention task 20, HC 69.4 n.a. D2 36 PFC Glucose ingestion enhances the lateral
and ventral PFC activation of the right
hemisphere to the two concurrent tasks
Gagnon et al. (2012)
12-week docosahexaenoic acid-rich ﬁsh
oil supplementation
Battery of cognitive tasks 65, HC 20.6 18–29 D14 2 PFC Dose response PFC activation Jackson et al. (2012)
Single dose green tea polyphenol
epigallocatechin gallate (135 mg)
Battery of cognitive tasks 27, HC 22 18–33 D14 12 PFC FC CBF decrease Wightman et al. (2012)
Single dose soybean peptide Battery of cognitive tasks 10, HC n.a. 20–25 D4 52 PFC FP, dlPFC activation (frequency band
amplitude increase)
Yimit et al. (2012)
Single dose caffeine (75 mg) Battery of cognitive tasks 20, HC 21.4 19–28 D14 12 PFC FC CBF decrease only in non-habitual
consumers
Kennedy and Haskell
(2011)
Single dose trans-resveratrol
(250/500 mg)
Battery of cognitive tasks 22, HC 20.2 18–25 D14 12 PFC Dose-dependent FC CBF increase Kennedy et al. (2010)
Casein hydrolysate drink ingestion;
carbohydrate drink
n.u. 11, HC 22.5 ± 2.3 21–28 D16 10 PFC Casein hydrolysate drink does not
change [tHb]; carbohydrate drink
increases [tHb]
Nakamura et al. (2010)
Single dose caffeine (180 mg) UKP calculation tests
before/after caffeine intake
14, HC n.a. 21–50 D11 2 PFC The same PFC activation before and after
caffeine intake
Higashi et al. (2004)
5-day creatine supplementation UKP calculation tests
before/after
24, HC 24.3 ± 9.1 n.a. D6 1 PFC Reduced left FC activation Watanabe et al. (2002)
Effects of food images
Visual stimulation: food photos Like/dislike test 5, HC 23.4 ± 3.4 n.a. D4 52 FP, FT FP activation Hosseini et al. (2011)
Visual: images of body types/high-calorie
food/attachment
Symptom-provocative
views task
13, HC; 12, AN 14.3 ± 1.3; 14.4 ± 1.3 n.a. D4 24 PFC No difference in PFC activation between
HC and AN viewing body types/food; AN
higher PFC activation viewing
mother–child attachment
Nagamitsu et al. (2010)
Visual stimulation: drinks photos Preference evaluation task 9, HC 24.0 ± 4.4 n.a. D7 14 PFC Medial PFC activation Luu and Chau (2009)
Visual stimulation: food photos Preference evaluation task 8, HC 23 18–30 D13 32 PFC vmPFC activation Shimokawa et al.
(2008)
[tHb]: total hemoglobin concentration; ADHD: attention-deﬁcit/hyperactivity disorder; AN: anorexia nervosa; BN: bulimia nervosa; CBF: cerebral blood ﬂow; CH: channels; D: dysosmia; dlPFC: dorsolateral prefrontal cortex; D1: BOM-L1W (Omega
Wave, Japan); D2:CW-6 (Techen, USA); D3: ETG-100 (Hitachi, Japan); D4: ETG-4000 (Hitachi, Japan); D5: ETG-7100 (Hitachi, Japan); D6: HEO-200 (Omron, Japan); D7: Imagent (ISS, USA); D8:NIRO-200 (Hamamatsu Photonics, Japan); D9:NIRO-300
(Hamamatsu Photonics, Japan); D10: OEG-16 (Spectratech, Japan); D11: OM-200 (Shimadzu, Japan); D12: OMM-2000 (Shimadzu, Japan); D13: OMM-3000 (Shimadzu, Japan); D14: OXYMON MkIII (Artinis, The Netherlands); D15:PSA-500 (Bio-
medical Sciences, Japan); D16: TRS-10 (Hamamatsu Photonics, Japan); ED: eating disorders; FOT: ﬁnger opposition task; FP: frontopolar; FT: frontotemporal; HC: healthy controls; lPFC: lateral prefrontal cortex; MA: mild Alzheimer; MCS: multiple
chemical sensitivity; n.a.: not available; n.u.: not utilized; OFC: orbitofrontal cortex; PFC: prefrontal cortex; RPST: rock-paper-scissors intentional loss task; TC: temporal cortex; TTT: tongue tapping task; UKP: Uchida–Kraepelin psychodiagnostic test;
VFT: verbal ﬂuency task; vmPFC: ventromedial prefrontal cortex; vlPFC: ventrolateral prefrontal cortex.
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complexity from dual channels to ‘whole-head’ arrays of several dozen
channels. Data processing/analysis methods permit topographical assess-
ment of real-time regional cortical hemodynamic changes. However, the
relatively low spatial resolution of fNIRS makes it difﬁcult to precisely
identify the activated cortical regions. Moreover, the fNIRS measure-
ments, being limited to the cortical surface, cannot examine the primary
and secondary taste areas, which are located deep inside the brain
(Okamoto and Dan, 2007). Therefore, deeper brain areas, such as ventral
striatum and hypothalamus, which would be key for investigating eating
behavior, can be explored only by fMRI and/or PET.
2.3.2. Application of fNIRS for mapping human cortical responses in the
context of food stimuli/intake and eating disorders
The use of fNIRS in the context of food stimuli/intake and eating
disorders studies represents a relatively novel application, as witnessed
by the limited number of publications: 39 over the last 10 years. Table 2
summarizes these studies. The related fNIRS resultsmainly include: 1) a
lower frontal cortical activation upon different cognitive conditions/
stimuli in patients with ED, and 2) the different activation patterns
over the frontal and temporal cortices upon different conditions/stimuli
(i.e. food taste, food ﬂavor, odor food components, nutrition/food com-
ponents ingestion, and food images) in healthy subjects. So far, few
forms of ED have been investigated by fNIRS. Only one study has report-
ed PFC responses to visual stimuli in AN patients (Nagamitsu et al.,
2010). The other 4 ED-related studies reported in Table 2, and the ex-
tensive fMRI literature (see García-García et al., 2013 review summariz-
ing 86 studies) suggest the existence of neural differences between
normal and abnormal eating behavior in response to the sight of food.
Recently, Bartholdy et al. (2013) have reviewed the studies in which
neurofeedback was combined with neuroimaging techniques, suggest-
ing the potential use of fNIRS for evaluating ED treatments. However,
the interpretation of the fNIRS ﬁndings might be complicated by the
longer scalp-to-cortex distance in some patients with severe AN as a
consequence of their brain alteration following gray matter volume re-
duction and/or cerebrospinal ﬂuid volume increase (Bartholdy et al.,
2013; Ehlis et al., 2014). Therefore, an assessment of the degree to
which cortical atrophy and scalp perfusion could affect the sensitivity
of fNIRS is essential for evaluating the usefulness of this technique ﬁrst
as a research tool in patients with severe AN.
Thirty-four out of the 39 studies have been carried out only in healthy
subjects (Table 2). Twenty studies of themhave demonstrated how fNIRS
canprovide a useful contribution tomap taste processingmainly localized
in the lateral prefrontal cortex (lPFC). Eleven studies are related to the ap-
plication of fNIRS in nutritional intervention studies in both acute and
chronic intervention paradigms (Jackson and Kennedy, 2013; Sizonenko
et al., 2013 for reviews). These studies have suggested that fNIRS is capa-
ble to detect the effect of nutrients and food components on PFC
activation.
Unfortunately, most of the studies reported in Table 2 have been
performed in small sample size, and the comparison between patients
and controls was often insufﬁcient. In addition, only a single fNIRS
study, carried out using a high-cost fNIRS instrument based on time-
resolved spectroscopy, has reported absolute concentration values of
O2Hb and HHb.
In most of the reported studies, fNIRS probes covered only frontal
brain regions. Therefore, the involvement of other cortical areas includ-
ing parietal, fronto-temporal, and occipital regions, which might be as-
sociated with visuospatial processing, attention, and other perceptive
networks, were not investigated. In addition, most of the studies have
reported only changes in O2Hbmaking a comparisonwith fMRIﬁndings
difﬁcult.
These preliminary studies indicate that, when used inwell-designed
studies, fNIRS neuroimagingmay be a useful tool in helping to elucidate
the effects of dietary intake/supplementation. In addition, fNIRS could
be easily adopted for: 1) evaluating the efﬁcacy of ED treatment pro-
grams and behavioral training programs, and 2) investigating the
inhibitory control of the dlPFC to visual food cues in healthy subjects
as well as in ED patients.
3. Non-invasive neuromodulation approaches: recent developments
and current challenges
3.1. Real-time fMRI neurofeedback and cognitive therapy
3.1.1. Introduction to neurofeedback in cognitive reappraisal
Cognitive reappraisal is an explicit emotion regulation strategy in-
volving the modiﬁcation of cognitive processes in order to alter the di-
rection and/or magnitude of an emotional response (Ochsner et al.,
2012). The brain systems that generate and apply reappraisal strategies
include the prefrontal, dorsal anterior cingulate (dACC), and inferior pa-
rietal cortices (Ochsner et al., 2012). These regions function tomodulate
emotional responses in the amygdala, ventral striatum (VS), insula, and
ventromedial prefrontal cortex (vmPFC) (Ochsner et al., 2012; Fig. 1).
Finally, the use of cognitive reappraisal strategies has been shown to
regulate appetitive responses to highly palatable foods via these same
neural systems (Kober et al., 2010; Hollmann et al., 2012; Siep et al.,
2012; Yokum and Stice, 2013).
Neurofeedback using functionalmagnetic resonance imaging (fMRI)
data is a non-invasive training method used to alter neural plasticity
and learned behavior by providing individuals with real time informa-
tion about their brain activity to support learned self-regulation of this
neural activity (Sulzer et al., 2013; Stoeckel et al., 2014; Fig. 2). Combin-
ing real time fMRI (rtfMRI) neurofeedback with cognitive reappraisal
strategies is a cutting-edge strategy for translating the latest advances
in neuroscience, clinical psychology, and technology into a therapeutic
tool that may enhance learning (Birbaumer et al., 2013), neuroplasticity
(Sagi et al., 2012), and clinical outcomes (deCharms et al., 2005). This
approach complements other existing neurotherapeutic technologies,
including deep brain and transcranial stimulation, by offering a non-
invasive alternative for brain disorders and it may add value above psy-
chotherapy alone, including cognitive behavioral therapy, by providing
information about how and where changes in cognitions are causing
changes in brain function (Adcock et al., 2005).
There appear to be abnormalities in the use of cognitive reappraisal
strategies and the brain systems that implement them that contribute to
disorders of ingestive behavior, including AN, BN, BED, obesity, and ad-
diction (Kelley et al., 2005b; Aldao and Nolen-Hoeksema, 2010; Kaye
et al., 2013). Across these disorders, there is often dysfunction in two
major brain systems that also have key roles in cognitive reappraisal:
one involving hypersensitivity to rewarding cues (e.g. VS, amygdala, an-
terior insula, vmPFC, including orbitofrontal cortex) and the other in-
volving deﬁcient cognitive control over food or other substance use
(e.g. anterior cingulate, lateral prefrontal cortex— lPFC, including dorso-
lateral prefrontal cortex — dlPFC). Novel interventions designed to di-
rectly target dysfunctional emotion regulation strategies and patterns
of neural activity may provide a new direction and hope for these
difﬁcult-to-treat disorders.
3.1.2. Cognitive reappraisal, obesity, and eating disorders
Obesity is one candidate disorder that will be used to illustrate how
this novel, neuroscience-driven intervention approach may be imple-
mented. Different studies suggest that obese versus lean individuals
show elevated reward region responsivity to images of high-fat/high-
sugar foods, which increases risk for weight gain (cf. Section 2.1). Fortu-
nately, cognitive reappraisals, such as thinking of the long-term health
consequences of eating unhealthy food when viewing images of such
foods, increases inhibitory region (dlPFC, vlPFC, vmPFC, lateral OFC,
superior and inferior frontal gyrus) activation and decreases reward re-
gion (ventral striatum, amygdala, aCC, VTA, posterior insula) and atten-
tion region (precuneus, posterior cingulate cortex — PCC) activation
relative to contrast conditions (Kober et al., 2010; Hollmann et al.,
2012; Siep et al., 2012; Yokum and Stice, 2013). These data suggest
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that cognitive reappraisalsmay reduce hyper-responsivity of reward re-
gions to food cues and increase inhibitory control region activation,
which is crucial because our environment is replete with food images
and cues (e.g. ads on TV) that contribute to overeating. Accordingly,
Stice et al. (2015) developed anobesity prevention program that trained
participants to use cognitive reappraisals when confronted with un-
healthy foods, reasoning that if participants learn to automatically apply
these reappraisals, they will show reduced reward and attention region
responsivity and increased inhibitory region responsivity to food images
and cues for high-fat/high-sugar food,which should reduce caloric intake.
Young adults at risk for weight gain by virtue of weight concerns (N=
148) were randomized to this newMinding Health prevention program,
a prevention program promoting gradual reductions in caloric intake
and increases in exercise (the HealthyWeight intervention), or an obesity
education video control condition (Stice et al., 2015). A subset ofMinding
Health and control participants completed an fMRI scan pre and post in-
tervention to assess neural responses to images of high-fat/sugar foods.
Minding Health participants showed signiﬁcantly greater reductions in
body fat than controls and percentage of caloric intake from fat and
sugar than Healthy Weight participants, though these effects attenuated
by 6-month follow-up. Further, Minding Health participants showed
greater activation of an inhibitory control region (inferior frontal gyrus)
and reduced activation of an attention/expectation region (mid cingulate
gyrus) in response to palatable food images relative to pretest and con-
trols. Although the Minding Health intervention produced some of the
hypothesized effects, it only affected some outcomes and the effects
often showed limited persistence.
It is possible that the addition of rtfMRI neurofeedback training to
the Minding Health intervention may lead to more persistent effects
and improved treatment outcomes. Given the emphasis on the use of
cognitive reappraisal in the Minding Health intervention, fMRI-based
neurofeedback was preferred compared to other, complementary tech-
nologies such as electroencephalography (EEG) due to the superior
spatial resolution of fMRI, including the ability to target subcortical
brain structures critical to the regulation of food intake behavior for
neurofeedback. The ﬁrst study demonstrating the therapeutic potential
of rtfMRI neurofeedback was published in 2005 (deCharms et al.,
2005). There have been several studies now demonstrating rtfMRI
neurofeedback-induced changes in brain function inmultiple structures
of relevance to disorders of ingestive behavior, including the amygdala
(Zotev et al., 2011; Zotev et al., 2013; Bruhl et al., 2014), insula (Caria
et al., 2007; Caria et al., 2010; Frank et al., 2012), aCC (deCharms et al.,
2005; Chapin et al., 2012; Li et al., 2013), and PFC (Rota et al., 2009;
Sitaram et al., 2011). Several groups have also reported successful appli-
cation of rtfMRI to modify cognitive and behavioral processes relevant
for the treatment of clinical disorders (for review of these studies see
deCharms, 2007; Weiskopf et al., 2007; deCharms, 2008; Birbaumer
et al., 2009; Caria et al., 2012; Chapin et al., 2012; Weiskopf, 2012;
Sulzer et al., 2013), including an application in the area of obesity
(Frank et al., 2012). For a review of potential applications of rtfMRI
Fig. 1.Amodel of the cognitive control of emotion (MCCE). (A) Diagramof the processing steps involved in generating an emotion and theways inwhich cognitive control processes (blue
box) might be used to regulate them. As described in the text, the effects of different emotion regulation strategies (the red arrows descending from the cognitive control processes box)
can be understood in terms of the stages of the emotion generation sequence that they inﬂuence. The pink box seen at the appraisal stage ismeant to indicate that neural systems involved
in generating emotion support this process. (B) Neural systems involved in using cognitive strategies, such as reappraisal, to regulate emotion (left, blue boxes), systems involved in gen-
erating those responses (left, pink boxes), and systemswith an undeﬁned or intermediary role in reappraisal (left, yellowboxes; adapted fromOchsner et al., 2012with permission). Brain
schematic representations were provided by Servier Medical Art (http://www.servier.fr).
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neurofeedback for disorders of ingestive behavior, see Bartholdy et al.
(2013).
3.1.3. Proof-of-concept for the use of rtfMRI neurofeedback with cognitive
reappraisal for the regulation of food intake behavior
As a proof-of-concept, Stoeckel et al. (2013a) completed a study
combining the use of cognitive reappraisal strategies (described
above) and rtfMRI neurofeedback in 16 healthy-weight participants
(BMI b 25) without a history of disordered eating who were acutely
fasted. In a pilot study, an independent sample of 5 participants were
able to improve control of inhibition-related (lateral inferior frontal cor-
tex), but not reward-related (ventral striatum), brain activation using
rtfMRI neurofeedback (Stoeckel et al., 2011). Therefore, lateral inferior
frontal cortex was selected as the target brain region of interest for
neurofeedback. Participants completed two neurofeedback visits,
1 week apart. At each visit, participants initially performed a functional
localizer task, the stop signal task, which is a well-known test of
inhibitory control (Logan et al., 1984) that activates lateral inferior fron-
tal cortex (Xue et al., 2008). Participants then attempted to self-regulate
brain activity within this region of interest using cognitive regulation
strategies while viewing highly palatable food images. While viewing
the food images, participants were asked to either mentalize their
urge to eat the food (crave or 'upregulation’) or consider the long-
term future consequences of over-consuming the food (cognitive reap-
praisal or ‘downregulation’). At the end of each neurofeedback training
trial, participants received feedback from the brain region identiﬁed by
the localizer scan using custom in-house software developed at the
Massachusetts Institute of Technology (for technical details, see Hinds
et al., 2011). Participants also recorded their subjective cravings in re-
sponse to the food images throughout the session. Compared to upreg-
ulation trials, participants had less reward circuit activity (ventral
tegmental area (VTA), VS, amygdala, hypothalamus, and vmPFC) and
decreased cravingwhen using reappraisal strategies (ps b 0.01). In addi-
tion, the difference in activity in the VTA and hypothalamus during up-
regulation vs. reappraisal was correlated with craving (rs = 0.59 and
0.62, ps b 0.05). Neurofeedback training led to improved control of lat-
eral inferior frontal cortex; however, this was not related to mesolimbic
reward circuit activation or craving. rtfMRI neurofeedback training led
to increased control of brain activity in healthy-weight participants;
however, neurofeedback did not enhance the effect of cognitive regula-
tion strategies onmesolimbic reward circuit activity or craving after two
sessions (Stoeckel et al., 2013a).
3.1.4. Consideration for rtfMRI neurofeedback experiments targeting
disorders of ingestive behavior
Before testing this protocol in individuals with disorders of ingestive
behavior, including obesity, it will be important to consider which brain
region(s) are good targets for rtfMRI neurofeedback training and how
best to represent neuropsychological functions at the neural systems
level. For example, the hypothalamus has a central role in the regulation
of ingestive behavior; however, it is a relatively small structure with sev-
eral subnuclei with heterogeneous functional properties that contribute
to the regulation of hunger, satiety, and metabolism, but also less closely
related functions such as sleep. Given the resolution of rtfMRI, it is possi-
ble that a neurofeedback signal from the hypothalamuswould include in-
formation from a combination of these subnuclei, which may impact the
effectiveness of efforts to improve voluntary regulation of a speciﬁc func-
tion (e.g. hunger). It is also important to consider the likelihood that the
targeted function is amenable to training. For example, it is possible that
targeting the homeostatic control of feeding represented in the hypothal-
amus and brainstem may lead to compensatory behaviors to defend the
set point of body weight given that these are central, highly conserved
neural circuits that control normal energy homeostasis. However, it may
be possible to target hedonic, cognitive control, or other “non-homeostat-
ic”mechanisms (and their supporting neural circuits) thatmay help indi-
viduals more effectively to adapt to their environment while minimizing
compensatory behaviors that may lead to persistent obesity. It is also un-
clear whether better outcomes would be expected from neurofeedback
from an anatomically-restricted brain region or set of brain regions or
whether a network approach using connectivity-based feedback or
multi-voxel pattern classiﬁcation (MVPA) may be preferable given the
regulation of ingestive behavior involves both homeostatic and non-
homeostatic mechanisms represented in a distributed neural circuitry in
the brain (Kelley et al., 2005a). An ROI-based approach could be used to
Fig. 2. Schematic of real-time functional magnetic resonance imaging (rtfMRI) control loop. Typically, echo planar imaging (EPI) images are extracted from themagnetic resonance (MR)
scanner online, analyzed by third-party software, and then presented back to the subject for the purposes of neural self-regulation (adapted fromWeiskopf et al., 2004) mEPI: multi-echo
EPI; EMG: electromyography.
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target a speciﬁc brain region (e.g., vmPFC for the regulation of subjective
reward value of highly palatable food cues). Another option is to
normalize disrupted functional connections between a set of brain
regions instantiating a well-characterized function (e.g., the entire
mesocorticolimbic reward system consisting of VTA-amygdala-VS-
vmPFC). MVPA may be preferable if there is a distributed set of multiple
brain networks that underlie a complex neuropsychological construct
such as cue-induce food craving. It may also be necessary to augment
rtfMRI neurofeedback training by including a psychological or cognitive
training intervention, such asMinding Health, prior to neurofeedback. Fi-
nally, it may be necessary to augment psychological or cognitive training
with adjunctive pharmacotherapy or device-based neuromodulation
such as TMS to enhance the efﬁcacy of neurofeedback training. For a
more detailed discussion of these and other issues of relevance to the de-
sign of rtfMRI neurofeedback studies of disorders of ingestive behavior,
see Stoeckel et al. (2014).
3.2. Transcranial magnetic stimulation (TMS) and transcranial direct-
current stimulation (tDCS)
3.2.1. Introduction to TMS and tDCS
Non-invasive neuromodulation techniques allow the external ma-
nipulation of the human brain in a safe manner, without the require-
ment of a neurosurgical procedure. Over the past two decades there
has been growing interest in the use of non-invasive neuromodulation
in neurology and psychiatry, motivated by the shortage of effective
treatments. The most commonly used techniques are transcranial mag-
netic stimulation (TMS) and transcranial direct current simulation
(tDCS). TMS is based on the application of rapidly changing magnetic
ﬁelds that are delivered with a coil encased in plastic that is placed
over the scalp of the subject (Fig. 3A). These varying magnetic ﬁelds
cause an induction of secondary currents in the adjacent cortex that
can be strong enough to trigger neuronal action potentials (Barker,
1991; Pascual-Leone et al., 2002; Hallett, 2007; Ridding and Rothwell,
2007). TMS can be administered in single or multiple pulses, also called
repetitive TMS (rTMS). In the case of tDCS,mild DC currents (typically in
the order of 1–2mA) are applied directly over the head through a pair of
saline-soaked electrode pads connected to a battery-like device
(Fig. 3B). Approximately 50% of the current delivered by tDCS pene-
trates the scalp and can raise or decrease the resting membrane poten-
tial of neurons in underlying areas (anodal or cathodal tDCS stimulation,
respectively), causing changes in spontaneous ﬁring (Nitsche et al.,
2008). rTMS and tDCS can induce transient/lasting changes that are be-
lieved to bemediated by changes in synaptic strength. A comprehensive
overview of these techniques and their mechanisms of action are be-
yond the scope of this section and can be found elsewhere (Pascual-
Leone et al., 2002; Wassermann et al., 2008; Stagg and Nitsche, 2011).
Table 3 presents a summary of key differences between TMS and
tDCS. While TMS and tDCS have been and still remain the dominant
techniques in the ﬁeld, other novel or modiﬁed forms of non-invasive
neuromodulation have been developed in recent years and are actively
under investigation, such as deep TMS (dTMS) (Zangen et al., 2005),
high-deﬁnition tDCS (HD-tDCS) (Datta et al., 2009), transcranial
alternate current simulation (tACS) (Kanai et al., 2008), or transcranial
random noise stimulation (tRNS) (Terney et al., 2008). Additional tech-
niques for neuromodulation are those that are invasive (cf. Section 4),
such as deep brain stimulation (DBS), or those that target peripheral
nerves, such as vagus nerve stimulation (VNS).
Over the past two decades there has been remarkable progress in
our understanding of the neurocognitive basis of human eating behav-
ior, obesity and eating disorders. A number of neuroimaging and neuro-
psychology studies have identiﬁed the crosstalk between reward and
cognition as a central component in the regulation of eating behavior
and body weight in humans (Alonso-Alonso and Pascual-Leone, 2007;
Wang et al., 2009a; Kober et al., 2010; Hollmann et al., 2012; Siep
et al., 2012; Vainik et al., 2013; Yokumand Stice, 2013). As research con-
tinues in this ﬁeld, the available knowledge makes it possible to begin
exploring interventions that shift from behavior to neurocognition as
the primary target. Overall, neuromodulatory techniques can bring
valuable insights and open novel therapeutic avenues in this new
Fig. 3. Pictures of (A) butterﬂy coils for transcranial magnetic stimulation (TMS) and (B) electrodes and battery for transcranial direct current stimulation (tDCS).
Table 3
Comparative between TMS and tDCS.
Characteristics Transcranial magnetic stimulation (TMS) Transcranial direct current stimulation (tDCS)
Spatial resolution Very good (approximately 1 cm3) Poor (conventional tDCS) to good (HD-tDCS)
Temporal resolution Excellent (ms) Poor (s)
Tolerability Very good to fair, depending on protocols Excellent to very good
Safety Good (can rarely cause seizures) Excellent
Cost High range (typically $30,000–$100,000) Low to middle range ($250–$10,000)
Portability Fair Excellent
Regulatory status Cleared for some speciﬁc devices and applications (depression, cortical mapping, migraine) Not cleared. Only off label application
Consumer versions No Yes
13D. Val-Laillet et al. / NeuroImage: Clinical 8 (2015) 1–31
Table 4
Summary of studies with TMS and tDCS in the ﬁeld of human eating behavior.
Study characteristics Subjects, status Stimulation protocol Main outcome measures Main ﬁndings References
TMS studies
Acute effects (single session);
parallel design, randomized,
double-blind, sham-controlled
n = 37 subjects (mean age: 30;
86.8% of women) with
bulimic-type eating disorders
Target: DLPFC; two groups: active (left DLPFC, 5 cm
anterior to hand motor area) and control (sham rTMS);
parameters: 1000 pulses, 10 Hz rTMS, 20 min,
intensity 110% motor threshold
Food craving (VAS) while exposed
to real food and a movie of food;
frequency of bingeing in a 24-hour
follow-up period
Decrease in food craving; reduction in bingeing
in 24 h post rTMS
Van den Eynde
et al. (2013)
Acute effects (single session);
crossover design, randomized,
single-blind, sham-controlled;
improved sham condition
matched for perceived
painfulness of the stimulation
n = 10 women (mean age: 28.3)
with frequent food cravings
(≥3 times/week during the past
month); 3-hour fasting
Target: DLPFC; two conditions: active (left DLPFC) and
control (sham rTMS); Parameters: 3000 pulses, 10 Hz
rTMS, 15 min, intensity 100% motor threshold
Food craving (VAS) while exposed
to food images
No differences between conditions Barth et al. (2011)
3-week intervention; parallel
design, randomized,
double-blind, sham-controlled;
preceded by 1-week of sham
rTMS in all participants
n = 14 women (mean age: 27.4)
with bulimia nervosa
Target: DLPFC; 1 week with sham rTMS before
randomization to avoid high placebo responders; two
groups: active (left DLPFC) and control (sham rTMS);
parameters: 3 weeks, 15 sessions, 2000 pulses per
session. 20 Hz rTMS, intensity 120% motor threshold
Change in binges and purges;
mood and compulsive symptoms
No differences between groups Walpoth et al.
(2008)
Acute effects (single session);
parallel design, randomized,
double-blind, sham-controlled
n = 28 women (mean age: 25.8)
with frequent food cravings
(≥3 times/week); 3–4 h fasting
Target: DLPFC; two groups: active (left DLPFC) and
control (sham rTMS); parameters: 1000 pulses, 10 Hz
rTMS, 20 min, intensity 110% motor threshold
Food craving (VAS); consumption
of snack foods
Decrease in food craving; no effect on snack
consumption
Uher et al. (2005)
tDCS studies
Acute effects (single session);
crossover design, randomized,
double-blind, sham-controlled
n = 9 women (mean age: 23.4);
all lean with frequent food
cravings (≥3 times/day); 3-hour
fasting
Target: DLPFC; two conditions: active (anode over
F4/cathode over F3) and control (sham tDCS);
parameters: 2 mA, 20 min, 35 cm2 sponge electrodes
EEG event-related potentials
during an Go/No-Go task; food
craving (VAS) while exposed to
real food and a movie of food;
snack intake; attentional bias for
food (eye tracking)
Reduction of the frontal N2 component and
enhancement of the P3a component of No-Go
responses; reduction in caloric intake
Lapenta et al.
(2014)
8-day intervention; crossover
design, randomized,
single-blind, sham-controlled
n = 14men (mean age: 24.8), all
lean, with low scores in
three-factor eating
questionnaire; 6-hour fasting
Target: DLPFC; two conditions: active (anode over an
area 5 cm anterior to the right motor cortex/cathode
over the left forehead) and control (sham tDCS);
parameters: 1 mA, 20 min, 35 cm2 sponge electrodes
Subjective appetite (ratings and
VAS); free eating from a
standardized multi-choice test
buffet
14% decrease in total calorie consumption, at
the expense of carbohydrates; decrease in
appetite: nonspeciﬁc and speciﬁc (sweets and
savory food)
Jauch-Chara et al.
(2014)
Acute effects (single session);
crossover design, randomized,
double-blind, sham-controlled
n = 17 women (mean age: 26.4;
29.4% of overweight) with
frequent food cravings (≥1/day)
Target: DLPFC; two conditions: active (anode over
F4/cathode over F3) and control (sham tDCS);
parameters: 2 mA, 20 min, 4 cm2 sponge electrodes
Food craving ratings while
viewing movies of food; temporal
discounting task; free eating test
Decrease in craving for sweets; no effect on
temporal discounting no change in free eating;
moderating effect of temporal discounting:
participants with more reﬂective choice
behavior showed more susceptibility to
anticraving effects of tDCS
Kekic et al. (2014)
Acute effects (single session), in
combination with an exercise
bout of about 200 calories;
crossover design, randomized,
single-blind, sham-controlled
n = 9 subjects (mean age: 24;
55% of men; all overweight or
obese), 2- to 3-hour fasting
Target: DLPFC; two conditions: active (anode over
F3/cathode over Fp2) and control (sham tDCS);
parameters: 2 mA, 20 min, 35 cm2 pads
Subjective appetite (VAS) Decrease in desire to eat with tDCS; greater
appetite suppression with the combination of
tDCS and exercise
Montenegro et al.
(2012)
Acute effects (single session);
crossover design, randomized,
single-blind, sham-controlled
n = 19 subjects (mean age: 32.5;
68.4% of women; about 58% of
overweight or obese) with
frequent food cravings
(≥3 times/week during the past
month); 4-hour fasting
Target: DLPFC; two conditions: active (anode over
F4/cathode over F3) and control (sham tDCS);
parameters: 2 mA, 20 min, standard sponge electrodes
Food craving and ability to resist
tasting (VAS) while viewing food
images; free consumption of
previously presented foods
Decrease in food craving, particularly for sweets
and carbohydrates; no change in food
consumption
Goldman et al.
(2011)
Acute effects (single session);
crossover design, randomized,
double-blind, sham-controlled
n = 23 subjects (mean age: 23.7;
91% of women) with frequent
food cravings (≥3 times/day);
3-hour fasting
Target: DLPFC; three conditions: active 1 (anode over
F3/cathode over F4), active 2 (anode over F4/cathode
over F3), control (sham tDCS); parameters: 2 mA,
20 min, 35 cm2 sponge electrodes
Food craving (VAS) while exposed
to real food and a movie of food;
snack intake; attentional bias for
food (eye tracking)
Decrease in food craving only in condition
active 1; decrease in snack intake in conditions
active 1 and 2; decrease in attentional bias for
food only in condition active 1
Fregni et al.
(2008)
rTMS: repetitive transcranial magnetic stimulation; tDCS: transcranial direct current stimulation; DLPFC: dorsolateral prefrontal cortex; VAS: visual analogue scale; Electrode montage for tDCS: F3 (left DLPFC), F4 (right DLPFC), Fp2 (right supra-
orbital); EEG: electroencephalography; N2, P3a: speciﬁc EEG electrophysiological measures.
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scenario that places neurocognition as a central component of human
eating behavior.
3.2.2. Summary of clinical studies to modify eating behavior and eating
disorders
Eating behavior is a recent application in the ﬁeld of non-invasive
neuromodulation, with the earliest study dating back to 2005 (Uher
et al., 2005). TMS and tDCS are the only techniques that have been
used in this context. Table 4 provides a summary of randomized, con-
trolled, proof-of-concept studies. To date, these studies have tested
acute, single-session effects only, with two exceptions: one study with
rTMS in bulimic patients (3 weeks), and a recent study with tDCS in
healthy men (8 days). The targeted area, dorsolateral prefrontal cortex
(dlPFC), is a complex brain region related to executive functions that
supports cognitive control of food intake. Overall, the underlying
hypothesis is that enhancing dlPFC activity may alter the reward–
cognition balance towards facilitation of cognitive control and possibly
suppression of reward-related mechanisms that drive food craving and
overeating. The speciﬁc dlPFC-dependent cognitive processes being
affected by rTMS or tDCS and mediating the observed behavioral effects
remain largely unknown. Possibilities include changes in reward valua-
tion mechanisms (Camus et al., 2009), attentional biases (Fregni et al.,
2008), or inhibitory control (Lapenta et al., 2014). rTMS studies have
targeted the left dlPFC only, via excitatory protocols (10 and 20 Hz).
tDCS studies have targeted both the right and left dlPFC, with slightly dif-
ferent approaches/montages. The majority of studies— all with tDCS and
onewith rTMS— have evaluated effects on food craving, subjective appe-
tite and food intake. Altogether, they have consistently found an acute
suppression in the scores of self-reported food craving and appetite mea-
sured by ratings or visual analogue scales (VAS). There is some indication
that the effect with tDCS may be more speciﬁc for craving of sweets.
Changes in food intake have been rather inconsistentwith a single session
of rTMS or tDCS. In the longest study to date with tDCS (8 days), the au-
thors found a 14% decrease in calorie consumption (Jauch-Chara et al.,
2014). An important bias in some studies is the use of a sham procedure
without any current ﬂow as control, instead of sham stimulation in areas
that are irrelevant to food intake for example. Since the stimulation is
sometimes perceptible by the patient, we cannot exclude a placebo effect
in some cases.
Studies with eating disorder patients so far have used only rTMS.
Several case reports (Kamolz et al., 2008; McClelland et al., 2013b)
and an open-label study (Van den Eynde et al., 2013) (not included in
the table) suggest potential for rTMS in anorexia nervosa, but ﬁndings
should be replicated in placebo-controlled trials. For the case of B N, an
early case report suggested potential beneﬁts with rTMS (Hausmann
et al., 2004), but this was not conﬁrmed in a subsequent clinical trial
that used this technique over 3 weeks (Walpoth et al., 2008). A recent
case study reported beneﬁcial effects using 10Hz rTMS applied over a dif-
ferent target, the dorsomedial prefrontal cortex, in a refractory patient
with BN (20 sessions, 4 weeks) (Downar et al., 2012). This brain region
represents a promising target given its general role in cognitive control,
speciﬁcally performance monitoring and action selection (Bush et al.,
2000; Krug and Carter, 2012), and its link with the clinical course of AN
and BN (McCormick et al., 2008; Goddard et al., 2013; Lee et al., 2014).
3.2.3. Future needs: from empirically-driven studies to rational andmecha-
nistic approaches
Results from these initial studies provide a good proof of concept for
the translation of non-invasive neuromodulation into the ﬁeld of eating
behavior. Potential applications can be the enhancement of cognitive
control and underlying brain regions to support successful weight loss
maintenance in obesity (DelParigi et al., 2007; McCaffery et al., 2009;
Hassenstab et al., 2012), or rebalancing ventral and dorsal brain systems
in AN and B N (Kaye et al., 2010). While the overall rationale is quite
clear, the speciﬁcs of using noninvasive neuromodulation in the treat-
ment of obesity and eating disorders are currently under investigation
and the best approaches and protocols remain to be deﬁned. Noninva-
sive neuromodulation could be used alone or in combination with
other strategies such as behavioral therapy, cognitive training, physical
ﬁtness and nutrition, to create synergistic effects. Aside from therapeu-
tic applications, neuromodulation techniques can be used to inform
diseasemechanisms, e.g. examining the causal involvement of a speciﬁc
region in a given cognitive process or behavioral manifestation
(Robertson et al., 2003). Recent studies have examined the potential
of TMS to quantify reward responses (Robertson et al., 2003) and results
from this line of work could eventually lead to the development of ob-
jective biomarkers that can help study eating phenotypes.
While there is a high potential for future uses of neuromodulation in
the ﬁeld of eating behavior, there are still many limitations and open
questions. Blinding is a key issue, called into question by one rTMS
study in food craving and a tDCS study where subjects were able to
guess the condition they had received with 79% accuracy (Barth et al.,
2011; Goldman et al., 2011). Future studies should consider parallel de-
signs to overcome this problem, or at least rule out the possibility of in-
complete blinding when crossover designs are used. Another need to
address in future studies is the addition of more clinically meaningful
outcomes. rTMS and tDCS have caused changes in measures that are
sensitive and valid in an experimental setting, e.g. visual analogue
scales, but their clinical relevance remains uncertain.
All studies to date have targeted the DLPFC, as in other applications
of tDCS and rTMS in neuropsychiatry. There is need to explore addition-
al targets; dorsomedial prefrontal cortex/dorsal anterior cingulate cor-
tex (daCC), parietal regions and anterior insular cortex are particularly
promising. Both rTMS and tDCS are currently optimized to target brain
regions located on the surface. Reaching deeper brain structures may
be more feasible with HD-tDCS, or with dTMS for the case of mid-
depth areas such as insular cortex (Zangen et al., 2005). A recently de-
scribed method for rTMS consists of guiding stimulation on the basis
of intrinsic functional connectivity determined by resting-state fMRI
(Fox et al., 2012a; Fox et al., 2012b). Aside from targeting brain regions
alone, non-invasive neuromodulation can be administered with simul-
taneous cognitive training. This approach may lead to more functional
effects (Martin et al., 2013; Martin et al., 2014) and is articularly suited
for eating disorders and obesity, where there are impairments in specif-
ic neurocognitive domains, such as executive functions, even though the
picture is complex (Alonso-Alonso, 2013; Balodis et al., 2013). The use
of cognitive performance and/or ways of measuring brain activity can
also facilitate target monitoring and overall contribute to optimize the
delivery of neuromodulation. A recent tDCS study points in that direc-
tion, with a combination of EEG event-related potentials and behavioral
measures of food craving and food intake (Lapenta et al., 2014).
More work is needed to understand potential sources of variability
in the response to neuromodulation. The majority of participants in
these rTMS/tDCS studies have been young women, with variable BMI.
Gender effects remain unaddressed, with no direct comparisons so far
betweenwomen andmen, but differences are likely based on the effect
of gender on brain correlates of appetite (Del Parigi et al., 2002; Wang
et al., 2009a). When studying food-related processes and mechanisms,
it is also important to consider the underlying variability in brain activ-
ity related to metabolic state. As mentioned in Table 4, subjects have
been stimulated typically in an intermediate state, i.e. about 2–4 h
after a meal. It is unknown whether different conditions can cause bet-
ter results. Another potential confounder that remains unaddressed is
the role of dieting. Patients with eating disorders and obesity usually
follow diets that can be quite restrictive and, more importantly, could
have substantial effects on brain excitability and also in the sensitivity/
response to neuromodulation (Alonso-Alonso, 2013). An additional fac-
tor is whether a person receives TMS or tDCS in a weight-reduced state
or in a weight-stable state, which would also have consequences in the
resting brain state and neuromodulatory response (Alonso-Alonso,
2013). Lastly, at a more technical level, individual head anatomy can
alter electric or electromagnetic transmission. This issue has been
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extensively addressed using computational models of tDCS (Bikson
et al., 2013). A particular concern in this regard is whether head fat, a
relatively resistive tissue, could affect current density distribution
(Nitsche et al., 2008; Truong et al., 2013).
Regarding side effects, both TMS and tDCS are non-invasive, safe and
rather painless techniques that are verywell tolerated in the vastmajor-
ity of cases (Nitsche et al., 2008; Rossi et al., 2009). The most common
adverse effects with rTMS is headache, which occurs approximately in
25–35% of patients during dlPFC stimulation, followed by neck pain
(12.4%) (Machii et al., 2006).With tDCS, a substantial proportion of peo-
ple (N50%) report transient sensations under the electrode that can be
deﬁned as tingling, itching, burning or pain, and are usually mild or
moderate (Brunoni et al., 2011). When designing a study it is important
to exclude participants with contraindications to receive either TMS or
tDCS, and collect adverse events in a systematicmanner. There are stan-
dardized questionnaires available for that purpose (Rossi et al., 2009;
Brunoni et al., 2011). The most worrisome adverse effect of non-
invasive neuromodulation is the induction of seizure, which has been
reported only a few times with rTMS (Rossi et al., 2009).
The ﬁeld of neuromodulation is expanding very quickly and it has
started to cross boundaries beyond the medical and research community
to curious individual consumers and recreational users. It is important
that we, the community of scientists working in neuromodulation,
remain committed to guarantee research integrity andmaintain high eth-
ical standards in the use of thesemethods. The possibility ofmanipulating
the human brain can be as fascinating and tempting as trying a new diet
to curb appetite, but it is important to remind that the current state of sci-
ence in this ﬁeld is far from being conclusive. And, as importantly, trans-
cranial devices are not playthings (Bikson et al., 2013).
4. Invasive neuromodulation strategies: recent developments and
current challenges
4.1. Overviewof the peripheral neuromodulation strategies in the context of
food intake and weight control
4.1.1. Changes in vagal signaling during obesity
The homeostatic control of food intake involves a complex, bidirec-
tional communication system between the periphery and the central
nervous system that has been extensively reviewed (Williams and
Elmquist, 2012). The vagus nerve, because it contains mainly afferents
neurons that arise from the gut, the pancreas and the liver, plays a key
role in this communication. In non-obese individuals, chemosensory
(acid-sensing ion channels) andmechanosensory vagal receptors signal
immediate availability of food (Page et al., 2012). Further, several
hormones including ghrelin, cholecystokinin (CCK) and peptide tyro-
sine tyrosine (PYY) have the capability to activate vagal afferents
(Blackshaw et al., 2007).
Aside fromanexcessive accumulation of fat, a substantial body of ev-
idence suggests that obesity and/or high fat diet is associatedwith alter-
ation of peripheral responses to nutrients. Studies in rodents subjected
to a high-fat diet (HFD), or in diet-induced obesity consistently show re-
duced suppressive effects of intestinal nutrients on food intake com-
pared to control animals (Covasa and Ritter, 2000; Little, 2010). This is
associated with a reduced sensitivity of jejunal afferents (primarily
vagal) to low-level distension and reduced excitability of identiﬁed jeju-
nal vagal afferents within the nodose ganglion to CCK and 5-HT expo-
sure (Daly et al., 2011). Corresponding reductions in vagal afferent
expression of receptors for CCK, 5-HT and other anorexic GI peptides
have been reported in the nodose ganglion (Donovan and Bohland,
2009). Additionally, HFD reduced the responses of gastric vagal tension
receptors to distension and augmented the inhibitory effect of ghrelin
on vagal afferents. Alternatively, while leptin potentiated vagalmucosal
afferent responses, potentiation of mucosal afferents by leptin was lost
after HFD (Kentish et al., 2012). The loss of vagal afferent signaling to-
gether with the altered processing of vagal signals within the dorsal
vagal complex suggest that resetting these sensitivities by chronic
vagal stimulation (VNS) might reduce overeating.
4.1.2. Effects of vagal stimulation
Unilateral left cervical vagal stimulation is approved for treatment-
resistant depression and intractable epilepsy in the European Union,
the United States and Canada. Epileptic patients reported frequently
changes in eating behavior with alteration in diet preferences (Abubakr
andWambacq, 2008). These reports generated further investigations, ini-
tially through pure serendipity, which subsequently used animal models
to evaluate the effects of VNS on food intake and related weight control
(for synthetic tables on VNS studies, please see Val-Laillet et al., 2010;
McClelland et al., 2013a). The original studies in 2001 of Roslin and
Kurian (2001) in dogs and the other from Krolczyk et al. (2001) in rats
suggested a decrease in weight gain or a weight loss during chronic
vagal stimulation. Surprisingly, despite different surgical approaches, the
results demonstrated by these authors were identical. Indeed, Roslin
and Kurian (2001) used a bilateral cuff placement within the thorax
(hence stimulating both dorsal and ventral vagal trunks) while Krolczyk
et al. (2001) used a cervical placement on the sole left vagus to be similar
with the clinical setup for intractable epilepsy. Since these pioneering
studies, several research groups, including us, have published positive re-
sults using various electrodes locations, electrodes set-up and stimulation
parameters. The ﬁrst attempt to evaluate the adequate location of the
electrodes for food intake control was performed by Laskiewicz et al.
(2003). They demonstrated that bilateral VNS is more effective than uni-
lateral stimulation. Using a large animal pre-clinical model, we used
juxta-abdominal bilateral vagal stimulation on the longest longitudinal
study performed to date. We show that chronic vagus nerve stimulation
decreased weight gain, food consumption and sweet craving in adult
obeseminipigs (Val-Laillet et al., 2010). Further, unlike others studies per-
formed in smaller animal models, efﬁcacy improves over time in a man-
ner comparable that already exempliﬁed in intractable epilepsy patients
(Arle and Shils, 2011).
Unfortunately, the positive results observed in almost all animal pre-
clinical studies have not been conﬁrmed in humans. Because of regula-
tory restraints, all human studies have been performed using left cervi-
cal vagal cuff only with stimulation settings similar or closely identical
to those used for depression or epilepsy. Despite using long-term stim-
ulation, weight loss was found in about half of the subjects (Burneo
et al., 2002; Pardo et al., 2007; Verdam et al., 2012). At present, no
clear explanation for these non-responsive subjects can be offered. A re-
cent study by Bodenlos et al. (2014) suggests that large BMI individuals
are less responsive to VNS than lean people. Indeed, in their study, VNS
suppressed food intake in lean patients only.
Several authors have investigated the physiological basis of VNS
with speciﬁc reference to the left cervical placement of the electrode.
Vijgen et al. (2013) have demonstrated in an elegant study combining
PET imaging of the brown adipose tissue (BAT) and a cohort of VNS ep-
ileptic patients that VNS signiﬁcantly increases energy expenditure.
Moreover, the change in energy expenditure was related to the change
in BAT activity suggesting a role for BAT in the VNS increase in energy
expenditure. VNS has been demonstrated to change brain activity
throughout the entire cerebrum (Conway et al., 2012) and modulate
the monoaminergic systems (Manta et al., 2013). In humans, left VNS
induced rCBF (regional cerebral brain ﬂow) decreases in the left and
right lateral OFC and left inferior temporal lobe. Signiﬁcant increases
were found also in the right dorsal anterior cingulate, left posterior
limb of the internal capsule/medial putamen, the right superior tempo-
ral gyrus. Despite the critical importance of these areas towards control
of food intake and depression, no correlation was found between brain
activation and the outcome of depression score after 12 months of VNS
therapy. Therefore, it remains to be demonstrated that the observed
brain activity changes are causative factors to explain VNS effects. The
demonstration in rats that VNSmodulates visceral pain-related affective
memory (Zhang et al., 2013) might represent an alternative pathway
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that could explain the beneﬁcial effects observed on about half of the
patients. Our early studies on brain activation after juxta-abdominal bi-
lateral VNSperformed in growing pigs (Biraben et al., 2008) using single
photon gamma scintigraphywas the ﬁrst to evaluate VNS effects on the
non-pathological brain.We showed the activation of two networks. The
ﬁrst one is associated with the olfactory bulb and primary olfactory
projections areas. The second one involves areas that are essential to in-
tegrate gastro-duodenal mechanosensory information (hippocampus,
pallidum) so to give a hedonic value to these. Similar results have
been reported in rats either using PET (Dedeurwaerdere et al., 2005)
or MRI (Reyt et al., 2010). Unlike behavioral effects that take several
weeks to be identiﬁed, alterations in brain metabolism identiﬁed by
PET imaging were present 1 week only after the onset of VNS therapy.
In our porcine model of juxta-abdominal VNS, the cingulate cortex, pu-
tamen, caudate nucleus and substantia nigra/tegmental ventral area, i.e.
themain rewardmeso-limbic dopaminergic network, presented chang-
es in brain metabolism (Malbert, 2013; Divoux et al., 2014) (Fig. 4). The
massive activation of the reward network at an early stage of the chron-
ic stimulation suggests that brain imagingmight be used as a tool to op-
timize the vagal stimulation parameters.
As with several others therapies, the relatively poor success of VNS
in obese humans could be explained by an insufﬁcient understanding
of the action of VNS on the brain networks controlling food intake.
Translation of animalmodels into clinical practicewas (too) quickwith-
out experimental clues towards a normalized procedure for stimulation.
For instance, as mentioned above, early human studies were performed
with unilateral cervical vagal stimulation whereas all animal studies
suggested that bilateral juxta-abdominal location for the stimulating
cuffs was more appropriate. Furthermore, we are still in need for early
clues to reﬁne stimulation parameterswithout having towait for chang-
es in body weight. It can be speculated that brain-imaging methods to-
gether with computational model of VNS (Helmers et al., 2012) might
be of signiﬁcant help towards this clinical requirement.
4.1.3. Effects of vagal blockade
Several patients after vagotomyperformed as a cure for ulcer disease
report short-term loss of appetite; less commonly, prolonged loss of ap-
petite and further weight loss or failure to regain weight have been
noted (Gortz et al., 1990). Bilateral truncal vagotomy has been used
historically as a treatment for obesity refractory to other therapies,
and has been associated with satiety and weight loss (Kral et al.,
2009). Based upon this observation and although that it has been re-
ported that the effects on body weight are lost over time (Camilleri
et al., 2008) and that truncal vagotomy was virtually ineffective to re-
duce solid food intake (Gortz et al., 1990), vagal blockade therapy was
tested in humanswith theprimary objective to reduceweight ofmorbid
obese individuals. Vagal blockade was performed bilaterally at the ab-
dominal level using high frequency (5 kHz) current pulses. The large
scale, long lasting study called EMPOWER (Sarr et al., 2012) demon-
strated that weight loss was not greater in treated compared to control.
Despite this therapeutic failure, Vbloc therapy in type 2 diabetic patients
(DM2) reduces the level of HbA1c and hypertension shortly after activa-
tion of the device (Shikora et al., 2013). This beneﬁt and the stability of
the improvement over time suggest that themechanisms of action may
be, at least in part, independent from weight loss. Since these parame-
ters are entirely related to fat deposition and truncal vagotomy led to
signiﬁcant reductions in diet-induced visceral abdominal fat deposition
(Stearns et al., 2012), it is quite possible that the efferent neurons
blocked by the therapy might be responsible for the improvements ob-
served in DM2 patients.
4.2. State of the art of deep brain stimulation (DBS) and its potential for
tackling obesity and eating disorders
4.2.1. Overview on the state of the art in DBS
4.2.1.1. Current therapeutic applications of DBS. Deep brain stimulation
(DBS) is a technique based on implanted electrodes for treating
neuromotor disorders such as Parkinson3s disease (PD), as well as epilep-
sy, while showing promise for psychological disorders like treatment-
resistant depression (TRD) and obsessive–compulsive disorders (OCD)
(Perlmutter and Mink, 2006).
The subthalamic nucleus (STN) is commonly targeted for PD, while
the anterior nucleus of the thalamus (ANT), subgenual cingulate
(Cg25), and nucleus accumbens (Nac) are respectively targeted for
epilepsy, TRD and OCD (Fig. 5). The penetration of DBS, roughly
10,000 patients per yearworldwide, isminuscule compared to the prev-
alence of treatment-resistant PD, epilepsy, and psychiatric disorders
(see allcountries.org; TRD: Fava, 2003; PD: Tanner et al., 2008; OCD:
Denys et al., 2010). This section is aimed at identifying these technolog-
ical developments and their potential to combat obesity and eating
disorders.
4.2.1.2. Traditional surgery planning in DBS. In the traditional deep-brain
therapy (DBT) framework, preoperative brain MRI is acquired, a stereo-
tactic frame is afﬁxed to the patient, who then undergoes a CT scan, and
the insertion trajectory is set based on the registered modalities and a
deep brain atlas in printed form (Sierens et al., 2008). This framework
places restrictions on the choice of approach, and surgical planning in-
volves considerable mental computation by the surgeon. Modern DBS
practice relies on intra-operative microelectrode recordings (MER) for
conﬁrmation comes at the cost of extended operating times and greater
potential for complications (Lyons et al., 2004). While MER use is com-
mon in PD, feedback on targeting success is not possible for many non-
motor disorders.
4.2.1.3. Potential complications of DBS. In traditional and image-guided
approaches, targeting does not account for brain shift, and this neglect
leads to a heightened risk of complications. While brain shift may be
negligible under some conditions (Petersen et al., 2010), other studies
suggest that shifts up to 4 mm can occur (Miyagi et al., 2007; Khan
et al., 2008). Theworst case is a cerebrovascular complication, especially
when multiple trajectories are used during exploration (Hariz, 2002).
Moreover, the risk of penetration of a ventricular wall is an important
Fig. 4. Changes in glucose metabolism observed via positron emission tomography (PET)
imaging after injection of 18FDG (ﬂuorodeoxyglucose), between vagal stimulated vs. sham
animals. N= 8 Yucatán minipigs in both groups. VNS (vagus nerve stimulation) therapy
was applied during 8 days on ventral and dorsal vagal trunks at the level of the abdomen.
The cuff electrodes were placed surgically using a coelioscopic approach. p b 0.0001 with
FDR (false discovery rate correction) (see text for details).
17D. Val-Laillet et al. / NeuroImage: Clinical 8 (2015) 1–31
consideration (Gologorsky et al., 2011), which correlates strongly with
neurological sequelae. Despite the foregoing, DBS still has a relatively
low complication rate compared to bariatric surgery (Gorgulho et al.,
2014) and recent DBS innovations will considerably improve the safety
and accuracy of this surgery.
4.2.2. Recent DBS innovations and emerging DBS therapies
A number of innovative techniques have been proposed in image-
guided DBS, improving the functionally descriptive aspects of surgery
planning. Most groups emphasize only a small number of these tech-
niques at once, which include 1) a digital deep-brain atlas depicting
deep-brain structures in humans (D3Haese et al., 2005; Chakravarty
et al., 2006) and animal models such as the pig (Saikali et al., 2010);
2) a surface model, featuring shape statistics, for registering an atlas to
patient data (Patenaude et al., 2011); 3) an electrophysiological data-
base with successful target coordinates (Guo et al., 2006); 4) a model
of venous and arterial structures, identiﬁed from the combination of
SusceptibilityWeighted Imaging and Time-Of-Flight angiographicmag-
netic resonance imaging (Bériault et al., 2011); 5) multi-contrast MRI
that directly delineates the basal ganglia structures through
coregistered images weighted on T1, R2* (1/T2*), and susceptibility
phase/magnitude (Xiao et al., 2012); 6) validation of deep brain therapy
through animal trials, mostly conﬁned to rodents (Bove and Perier,
2012) but also applied to (mini)pigs (Sauleau et al., 2009a; Knight
et al., 2013); 7) computer simulation of DBS (McNeal, 1976;
Miocinovic et al., 2006), using a ﬁnite element model of voltage distri-
bution of the stimulating electrode as well as an anatomical model of
the stimulated neural tissue; and 8) connectomic surgery planning for
DBS (Henderson, 2012; Lambert et al., 2012), where patient-speciﬁc
white matter tracts identiﬁed from diffusion tensor/spectrum imaging
(DTI/DSI) are exploited for effective targeting.
The above technologies relate to preoperative planning; Meanwhile,
very little effort has been devoted to intraoperative accuracy. The main
exception is intraoperative MRI (ioMRI)-guided DBS, which was pro-
posed in Starr et al. (2010), using an MRI-compatible frame. Another
recent intraoperative development is closed-loop deep-brain therapy de-
livery, based on electrical or neurochemical feedback (Rosin et al., 2011;
Chang et al., 2013).
Last, highly selective therapies have been proposed for the treat-
ment of epilepsy, which target mutated genes that modulate ion chan-
nels (Pathan et al., 2010).
Therapies that address molecular pathways speciﬁc to PD (LeWitt
et al., 2011), and TRD (Alexander et al., 2010) are also being developed.
In this kind of deep-brain therapy, the electrical stimulation is replaced
by the infusion of substances that modulate the neurotransmission
locally.
4.2.3. Applicability of DBS in the context of obesity and eating disorders
4.2.3.1. The effects of DBS on eating behavior and body weight. In a compre-
hensive review, McClelland et al. (2013a) presented evidence from
human and animal studies on the effects of neuromodulation on eating
behavior and body weight. Four studies observed clinical improvements
and weight gain in patients with anorexia nervosa (AN) treated with
DBS (in the Cg25, Nac, or ventral capsule/striatum – VC/VS) (Israel et al.,
2010; Lipsmanet al., 2013;McLaughlin et al., 2013;Wuet al., 2013); a sin-
gle case report showed a signiﬁcant weight loss in a DBS-treated patient
suffering from obsessive–compulsive disorders (Mantione et al., 2010);
and eleven studies reported either over-eating and/or increases in
Fig. 5. DBT targets: (A) subthalamic nucleus (coronal view, yellow, labeled “STN”); (B) anterior nucleus of thalamus (3D rendering, dark blue, labeled “anterior”); (C) subgenual anterior
cingulate (medial view, region high-lighted in red); (D) nucleus accumbens (medial view, blue circle) (Wiki).
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cravings, weight gain and BMI following DBS of the STN and/or globus
pallidus — GP (Macia et al., 2004; Tuite et al., 2005; Montaurier et al.,
2007; Novakova et al., 2007; Bannier et al., 2009; Sauleau et al., 2009b;
Walker et al., 2009; Strowd et al., 2010; Locke et al., 2011; Novakova
et al., 2011; Zahodne et al., 2011). In patients treated for PD, we can as-
sume that the decrease inmotor activity, and thus in energy expenditure,
might explain part of the increasedweight gain, even thoughAmami et al.
(2014) recently suggested that compulsive eating may be speciﬁcally re-
lated to STN stimulation.
Amongst the 18 animal studies (mainly rats) assessing food intake
and weight further DBS (McClelland et al., 2013a), only two stimulated
theNac or dorsal striatum,while the others focused on the lateral (LHA)
or ventromedial (vmH) hypothalamus. Halpern et al. (2013) showed
that DBS of Nac can reduce binge eating, while van der Plasse et al.
(2012) interestingly revealed different effects on sugar motivation and
food intake according to the sub-area of Nac stimulated (core, lateral
or medial shell). LHA stimulation mostly induced food intake and
weight gain (Delgado and Anand, 1953; Mogenson, 1971; Stephan
et al., 1971; Schallert, 1977; Halperin et al., 1983), even though Sani
et al. (2007) showed a decreased weight gain in rats. vmH stimulation
decreased food intake and/or weight gain in most cases (Brown et al.,
1984; Stenger et al., 1991; Bielajew et al., 1994; Rufﬁn and Nicolaidis,
1999; Lehmkuhle et al., 2010), but two studies showed increased food
intake (Lacan et al., 2008; Torres et al., 2011).
Tomycz et al. (2012) published the theoretical foundations and de-
sign of the ﬁrst human pilot study aimed at using DBS to combat obesity
speciﬁcally. Preliminary results from this study (Whiting et al., 2013) in-
dicate that DBS of the LHA may be applied safely to humans with intrac-
table obesity, and induce someweight loss undermetabolically optimized
settings. Two clinical trials on DBS for AN are also in progress according to
Gorgulho et al. (2014), which demonstrate that DBS is a hot topic and
promising alternative strategy to combat obesity and eating disorders.
4.2.3.2. What the future has to offer. Most of the DBS studies aimed at
modifying eating behavior or body weight in animal models were per-
formed one to several decades ago, and almost exclusively focused on
the hypothalamus, which plays a pivotal role in homeostatic regula-
tions. The explosion of functional brain imaging studies and the descrip-
tion of brain anomalies in the reward and dopaminergic circuits of
subjects suffering from obesity or eating disorders show that hedonic
regulations are of the utmost importance for food intake control.
The most effective treatment against obesity remains bariatric sur-
gery, and especially the gastric bypass surgery. We have a lot to learn
from the effectiveness of this treatment in terms of brain mechanisms
and potential targets for DBS, and recent studies managed to describe
the surgery-induced remodeling of brain responses to food reward,
hunger or satiety (Geliebter, 2013; Frank et al., 2014; Scholtz et al.,
2014). The Nac and PFC are part of the brain areas impacted. Knight
et al. (2013) showed in pigs that DBS of the Nac canmodulate the activ-
ity of psychiatrically important brain areas, such as the PFC, for which
anomalies were described in obese humans (Le et al., 2006; Volkow
et al., 2008) and minipigs (Val-Laillet et al., 2011). All the DBS improve-
ments described beforehand will help targeting the best structures and
copingwith brain shift, and large animal models such as theminipig are
an asset in perfecting surgical strategies.
Basal nuclei have a complex ‘somatotopy’ (Choi et al., 2012), and DA
spatial and temporal release involves distinct neuralmicrocircuitswith-
in subregions of these nuclei (Besson et al., 2010; Bassareo et al., 2011;
Saddoris et al., 2013), which means that small errors in terms of
targeting can have dramatic consequences in terms of neural networks
and neurotransmission processes impacted. Once this challenge will be
achieved, highly innovative deep-brain therapies could target some
functions of the dopaminergic system for example, which is altered in
patients suffering from obesity (Wang et al., 2002; Volkow et al.,
2008) and animal models of addictive-like cravings or bingeing
(Avena et al., 2006; Avena et al., 2008), with the aim of normalizing
the functional processes of the DA system (as in Parkinson3s for the
motor disorders). Even though ﬁndings relating obesity and DA abnor-
malities appear sometimes inconsistent, it is probably because incorrect
interpretations or comparisons have been done. Most of the discrepan-
cies in the DA literature arose because different pathological stages (dif-
ferent degrees of obesity with different comorbidities, reward deﬁcit vs.
surfeit phenotypes), brain processes (basal activity vs. response to food
stimuli), or cognitive processes (liking vs. wanting, occasional vs.
habitual consumption) were compared. Before proposing a DBS strate-
gy, there is a need for phenotyping patients in terms of neural circuits/
functions impacted. For example, the individual reward sensitivity phe-
notype may determine the treatment target in terms of goal brain
change (i.e. increased/decreased DA regions responsivity for deﬁcit vs.
surfeit phenotypes, respectively). In other patients for whom there is
no alteration of the reward circuit but rather neural abnormalities in
metabolic centers (such as the hypothalamus), the DBS strategy might
be completely different (e.g. modulate the LHA or vMH activity in AN
or obese patients to stimulate or decrease food intake, respectively).
Real-time fMRI neurofeedback combinedwith cognitive therapy (cf.
Section 3.1) might also be used for closed-loop DBS therapy. Even
though it has never been tested in our knowledge, the efﬁcacy of
targeting speciﬁc nuclei for DBS might be validated through its ability
to improve real-time brain and cognitive processes related to self-
control over highly palatable food stimuli (Mantione et al., 2014). This
approach might be used to ﬁnely tune the DBS parameters and location
tomaximize its impact on speciﬁc cognitive tasks or processes (e.g. self-
control over palatable foods).
Overall, these data offer a large ﬁeld of research and developments
to improve DBS surgery and make it, one day, a safer, ﬂexible and re-
versible alternative to classical bariatric surgery.
5. General discussion and conclusions: the brain at the core of
research, prevention and therapy in the context of obesity and
eating disorders
As described in this review, neuroimaging and neuromodulation ap-
proaches are emergent and promising tools to explore the neural vul-
nerability factors and obesity-related brain anomalies, and eventually
to provide innovative therapeutic strategies to combat obesity and ED.
The different sections of this review article can raise several questions
in terms of implementation of these tools in fundamental research, pre-
vention programs and therapeutic plans. How can these new technolo-
gies and exploratory approaches ﬁnd a placewithin the currentmedical
workﬂow, from prevention to treatment? What are the requisites for
their implementation, for which added value in comparison to existing
solutions, and where could they slot into the current therapeutic plan?
Toanswer these questions,we propose to initiate three debates thatwill
inevitably need further work and reﬂection. First, we will discuss the
possibility to identify new biological markers of key brain functions.
Second, we will highlight the potential role of neuroimaging and
neuromodulation in individualizedmedicine to improve the clinical path-
ways and strategies. Third,wewill introduce the ethical questions that are
unavoidably concomitant to the emergence of new neuromodulation
therapies in humans.
5.1. Towards new biological markers?
“It is far more important to know what person the disease has than
what disease the person has.” This quote from Hippocrates bears the
quintessence of preventive medicine. Indeed, reliable prediction and ef-
ﬁcient prevention are the ultimate objective in public health. Similarly,
accurate diagnosis, prognosis and treatment are mandatory for a good
medical practice. But all of these cannot be reached without a good
knowledge of the healthy and ill (or at risk) individual phenotypes,
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which can be achieved through the description and validation of consis-
tent biological markers.
Psychiatric studies extensively described the symptomology as well
as the environmental and behavioral risk factors underlying ED, while
obesity has been described through the lenses of multiple disciplines
as a multifactorial disease with a complex etiology. Despite all of this
knowledge, accurate biomarkers or clinical criteria are still lacking and
obsolete indices (such as BMI) are still used all over the world to deﬁne
and categorize patients. Yet, as reminded by Denis and Hamilton
(2013), many persons classiﬁed as obese (BMI N 30) are healthy and
should not be treated and categorized as diseased. On the contrary, sub-
jects that are not considered at risk with classical clinical criteria might
show a real vulnerability with more accurate markers, as described for
the TOFI sub-phenotype (i.e. thin-on-the-outside, fat-on-the-inside),
characterizing individuals at increased metabolic risk with normal
bodymass, BMI andwaist circumference, but with abdominal adiposity
and ectopic fat that MRI and MRS phenotyping can help to diagnose
(Thomas et al., 2012). In the context of neuroimaging, neural vulnerabil-
ity factors could help predicting a risk for further weight gain or suscep-
tibility to contract a contentious relationship with food, as described in
Burger and Stice (2014). For obvious practical and economical reasons,
this approach could not be used for a systematic screening, but might
be proposed to subjects that are particularly at risk, because of an unfa-
vorable genetic or environmental ground. Since plasmatic gut-brain
obesity-associated biomarkers were found to be associated with
neurocognitive skills (Miller et al., 2015), their detection could advocate
the collection of further functional biomarkers at the brain level and
contribute to a step-by-step diagnosis. Identifying neural risk factors
in people at risk, preferably in the young age, might guide further inter-
ventions (e.g. cognitive therapy) for pre-symptomatic treatment of
obesity or eating disorders. For example, reward sensitivity phenotype
may dictate the treatment target in terms of goal brain change (i.e.
increased/decreased reward regions responsivity for deﬁcit vs. surfeit
phenotypes, respectively). Another example is the case of patients pre-
senting symptoms that are common to different diseases and for which
speciﬁc explorations are required. Some gastrointestinal diseases com-
monly mimic the presentation of eating disorders, which incites the cli-
nician to consider a broad differential diagnosis when evaluating a
patient for an eating disorder (Bern and O3Brien, 2013). New neuropsy-
chiatric markers would consequently help diagnosis and should be
added to the battery of decision criteria available.
Omics approaches, referring to innovative technology platforms such
as genetics, genomics, proteomics, andmetabolomics, can provide exten-
sive data of which the computationmight lead to the formulation of new
biomarkers for prediction and diagnosis (Katsareli and Dedoussis, 2014;
Cox et al., 2015; van Dijk et al., 2015). But the integration between
omics and imaging technologies should potentiate the deﬁnition of
these biomarkers, through the identiﬁcation of organ-speciﬁc (notably
brain-speciﬁc) metabolisms and culprits associated with diseases
(Hannukainen et al., 2014). As described in the ﬁrst section of this re-
view, neural vulnerability factors could appear before the onset of ED
or weight problems, highlighting the possible existence of subliminal
predictors that brain imaging only might reveal.
Radiomics is a newdiscipline referring to the extraction and analysis
of large amounts of advanced quantitative imaging features with high
throughput frommedical images obtainedwith computed tomography,
PET, or structural and functional MRI (Kumar et al., 2012; Lambin et al.,
2012). Radiomics has been initially developed to decode tumor pheno-
types (Aerts et al., 2014), including brain tumors (Coquery et al., 2014),
but could be applied to other medical ﬁelds than oncology, such as eat-
ing disorders and obesity. As reminded in Section 2.2, the combination
of imaging modalities holds potential for future studies to decipher
the neuropathological mechanisms of a disease or disorder. Radiomics
(or neuromics when applied to brain imaging) could merge in the
same individual some information about brain activity and cognitive
processes (via fMRI, fNIRS, PET or SPECT) (see Section 2.1), availability
of neurotransmitters, transporters or receptors (via PET or SPECT) (see
Section 2.2), focal differences in brain anatomy (via voxel-based mor-
phometry — VBM) or connectivity (via diffusor tensor imaging – DTI)
(Karlsson et al., 2013; Shott et al., 2015), brain inﬂammatory status
(via PET or MRI) (Cazettes et al., 2011; Amhaoul et al., 2014), etc. On
the basis of these multimodal information, neuromics could further
generate synthetic brain mapping to provide an integrative/holistic in-
sight on brain anomalies associated with loss of food intake control or
ED. Moreover, this combination of neurological information might
help clarifying some discrepancies between studies, or apparent incon-
sistent ﬁndings such as those highlighted in the literature relating BMI
and DA signaling for example. Indeed, these discrepancies might de-
pend on the interpretation of studies that have looked at different as-
pects of dopamine signaling, or that compared processes (associated
to cognitive functions) that were not comparable.
These biomarkers could be used to phenotype patients with a diag-
nosis of obesity and/or ED, aswell as establish prognosis further speciﬁc
interventions. They could also be used in prevention programs to iden-
tify subjects with neural vulnerability factors and provide some recom-
mendations to prevent the onset of behavioral and health problems. In
terms of therapy, radiomics/neuromics might also be used before
selecting brain target(s) for neuromodulation, because the information
gathered through this method might help predicting the consequences
of neurostimulation on the activation of neural networks or the modu-
lation of neurotransmission.
5.2. Neuroimaging and neuromodulation in the scope of personalized
medicine
Personalized (or individualized) medicine is a medical model that
proposes the customization of healthcare using all clinical, genetic and
environmental information available, with medical decisions, practices,
and/or products being tailored to the individual patient. As reminded by
Cortese (2007), individualized medicine is in a pivotal position in the
evolution of national and global health care in the 21st century, and
this assertion is particularly true for nutritional disorders and diseases,
given the societal and economical burden that obesity represents in
the world for example, as well as the complexity and diversity of
obese phenotypes (Blundell and Cooling, 2000; Pajunen et al., 2011).
Advances in computational power and medical imaging are paving the
way for personalized medical treatments that consider a patient3s
genetic, anatomical, and physiological characteristics. In addition to
these criteria, cognitive measurements related to eating behavior (see
Gibbons et al., 2014 for a review) should be used in conjunction with
brain imaging because linking imaging data with cognitive processes
(or biological measures) can potentiate the analysis and discrimination
power.
Once the patient and the disease are well portrayed, the question of
the best suitable therapy arises. Of course, individual history (andnotably,
previously unsuccessful therapeutic attempts) is particularly important.
There is a graduation in both the severity of the disease and the degree
of invasiveness of treatments available (Fig. 6A). Obviously, basic require-
ments for a healthy lifestyle (i.e. balanced diet, minimal physical activity,
good sleep and social life, etc.) are sometimes difﬁcult to achieve formany
people, and never sufﬁcient for those who went beyond a particular
threshold in the disease progression. The classical therapeutic treatment
plan then includes psychological and nutritional interventions, pharma-
cological treatments and, in pharmacorefractory patients, the logical
next step is bariatric surgery (for morbid obesity) or hospitalization (for
severe eating disorders). All the neuroimaging and neuromodulation
strategies presented in this review can slot into the possible therapeutic
plan at different levels, therefore at different stages of a disease, from
identiﬁcation of neural vulnerability traits to treatment of severe forms
of the disease (Fig. 6A). Moreover, as illustrated in Fig. 6B, all the
neuromodulation approaches presented do not target the same brain
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structures or networks. The PFC, which is the primary target for transcra-
nial neuromodulation strategies (e.g. TMS and tDCS), sends inhibitory
projections to the orexigenic network but also has a major role in mood,
food stimuli valuation, decision-making processes, etc. While rtfMRI
neurofeedback could target virtually any moderate-sized brain region,
existing studies mainly focused on the PFC, the ventral striatum, but
also the cingulate cortex, which is very important for attentional process-
es. Lastly, in the context of nutritional disorders, DBS itself can target very
different deep-brain structures, such as reward or homeostatic regions
(Fig. 6B). As a consequence, the choice of a neuromodulation strategy
cannot rest on a single criterion (e.g. balance between the severity of dis-
ease— e.g. high BMI with comorbidities— and the invasiveness of thera-
py), but on multiple assessment criteria, of which some of these are
directly related to the patient3s phenotype and someothers to the interac-
tion between patient and therapeutic option (Fig. 6C). For some obese pa-
tients, stimulating the hypothalamus via DBS for example might be
ineffective or counterproductive if their condition takes its roots in
anomalies of the brain reward circuit. There is consequently a great
danger (the least being wasting time and money, the worst being
worsening the patient3s condition) in testing neuromodulation in
patients before knowing which regulation process to target — and
if the patient indeed develops iatrogenic neurobehavioral anoma-
lies related to this process.
In the future, computational brain network models should play a
major role in integrating, reconstructing, computing, simulating and
predicting structural and functional brain data from various imaging
modalities, from individual subjects to entire clinical populations. Such
models could integrate functionalities for the reconstruction of structur-
al connectivity from tractographic data, the simulation of neural mass
models connected by realistic parameters, the computation of individu-
alized measurements used in human brain imaging and their web-
based 3D scientiﬁc visualization (e.g. The Virtual Brain, Jirsa et al.,
2010), leading eventually to pre-operative modeling and predictions
in the ﬁeld of therapeutic neuromodulation.
Fig. 6. Schematic representation showing how potential neurotherapeutic strategies could be included in the therapeutic treatment plan for patients suffering from obesity and/or eating
disorders. (A) Simpliﬁed therapeutic treatment plan categorizing the different options according to the degree of severity of the patient3s condition (BMI, comorbidities, etc.) and/or the
degree of invasiveness of the interventions (in green: prevention programs and basic behavioral requirements for a healthy lifestyle; in blue: minimally invasive interventions; in red:
invasive interventions requiring surgery/anesthesia). In the dotted box are indicated the therapeutic optionsdiscussed in the review. (B) Potential neurotherapeutic strategies against obe-
sity and/or eating disorders, which target speciﬁc brain areas or complete neural networks regulating food intake, reward, attention, and homeostasis. (C) Examples of criteria analysis for
the assessment of therapeutic options for an individual patient. Acceptability (pre- or post-intervention) of the therapy is patient-dependent. Some criteria are therapy-dependent, such as
the invasiveness, technical nature, reversibility, and cost. The efﬁcacy and adaptability of the therapy depend on the interaction between patient and therapy, and can be estimated upon
data from a characterized clinical population. Adequation between therapy and patient is conditioned by all the aforementioned criteria, but also by external factors such as the social en-
vironment, the geographical/temporal availability of therapy, and the healthcare system the patient depends on. On the schematic three hypothetical intervention strategies to treat obe-
sity in a lambda patient, e.g. a diet (in green), a minimally invasive therapy (in blue), and an invasive therapy (red) are represented. (D) In the context of individualized medicine, the
absolute requirement is a good phenotyping of the clinical populations and individual patients, but also a good knowledge of the population/individual health trajectories. According
to the type of disease/disorder, the individual history, and the degree of severity of the patient3s condition, different therapeutic options can be considered. But within a given clinical pop-
ulation (e.g. morbidly obese), different phenotypes can exist and condition the choice of the treatment. Neuroimaging can help identifying neural vulnerability factors and markers,
selecting the best treatment option, and shaping therapeutic strategies (e.g. rtfMRI neurofeedback or brain target identiﬁcation for neuromodulation protocols).
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5.3. Ethics related to novel diagnostic and therapeutic tools
As described in this paper, the battle against obesity and eating dis-
orders has given rise to many new interdisciplinary developments.
Novel less invasive treatments (in comparison to classical bariatric sur-
gery for example) arewithin scrutiny in research and clinics. However, a
sound critical attitude towards these novel techniques should be main-
tained especially before their clinical application. As reminded in
Section 3.2, even minimally invasive neuromodulation techniques are
not playthings (Bikson et al., 2013), and can have neuropsychological
consequences that are not anodyne. Due to our current inability to un-
derstand the intricacies of brain modulations and their consequences
on cognitive processes, eating behavior and body functions, it is crucial
to remember another Hippocrates3 aphorism: “ﬁrst do no harm”. Fur-
ther preclinical studies in relevant animal models (e.g. pig models,
Sauleau et al., 2009a; Clouard et al., 2012; Ochoa et al., 2015) are thus
mandatory, along with extensive brain imaging programs to reveal
the individual phenotypes and histories (Fig. 6D) that could shape pre-
vention programs and possibly justify the use of neuromodulation
therapy.
To be implemented in the therapeutic treatment plan against obesi-
ty and eating disorders, neuromodulation strategies must have higher
assessment scores than classical options, and this assessmentmust inte-
grate various criteria such as acceptability, invasiveness, technical na-
ture (i.e. technologies and skills required), reversibility, cost, efﬁcacy,
adaptability and ﬁnally, adequation with the patient (Fig. 6C). The
main advantages of neuromodulation approaches in comparison to
classical bariatric surgery are: minimal invasiveness (e.g. DBS does not
systematically require general anesthesia and leads to less comorbidi-
ties than a gastric by-pass), high reversibility (neuromodulation can
be stopped immediately if problematic — even though insertion of
deep-brain electrodes can induce residual lesions throughout the de-
scent), adaptability/ﬂexibility (brain target and/or stimulation parame-
ters can be easily and quickly modiﬁed). But these advantages are not
sufﬁcient. The cost/advantage balance of each approachmust be studied
accurately, and the efﬁciency (cross between efﬁcacy and level of
investment, i.e. time,money, energy) of the alternative technique in im-
proving life expectancymust compete with that of classical techniques.
Minimally invasive and less costly neuroimaging and neuromodulation
methods must receive a particular interest because they will permit a
more important and widespread penetration in healthcare systems
and populations. We gave the example of fNIRS and tDCS as non-
invasive, relatively cheap and portable technologies, in comparison to
other imaging and neuromodulation modalities that are costly, depen-
dent on high-tech infrastructures, and consequently not readily avail-
able. Also, it is important to remind that, in the case of bariatric
surgery, the aim is not to lose themostweight possible but to limitmor-
tality and comorbidities associated with obesity. Some therapeutic
options might be less effective than classical bariatric surgery to lose
weight quickly but could be as efﬁcient (or even better) to improve
health on the long term, whichmeans that the success criteria of (pre)-
clinical trials should sometimes be revised or augmented with criteria
related to the improvement of neurocognitive processes and control be-
havior, rather than mere weight loss (which is very often the case).
Once again, a lot of obese people are satisﬁed with their own lives/
conditions (sometimes wrongfully) and some obese are indeed
completely healthy. As a matter of fact, recent sociological phenomena,
especially in North America, led for example to the emergence of fat
acceptance movements (Kirkland, 2008). Such a phenomenon is far
frombeing anecdotic orminor in terms of sociological impact on politics
and healthcare systems, because it focuses on civil rights consciousness,
freewill and discrimination, i.e. questions that affect directly a lot of peo-
ple (in the USA, two thirds of the population is overweight, one third is
obese). First, some people might perceive neuroimaging-based preven-
tion and diagnosis as stigmatizing tools, which necessitates to focus sci-
entiﬁc communication on the main objectives of this approach, i.e.
improving vulnerability detection and healthcare solutions. Second,
whatever the method employed, artiﬁcially modifying brain activity is
not trivial, because the intervention can modify conscious and uncon-
scious functions, self-control, and decision-making processes, which is
very different than aiming at correcting motor functions such as for
DBS and Parkinson3s disease. Soda taxes and other dissuasive measures
to ﬁght obesity are usually unpopular and reproved, because it is some-
times perceived as paternalism and an affront against freewill (Parmet,
2014). But let3s think about neuromodulation: Instead of increasing the
monetary value of palatable foods, the aim of neuromodulation is to de-
crease the hedonic value people attribute to these foods, within their
brain. We must foresee that a technology that could change or correct
mental processes will inexorably hatch a serious debate on bioethics,
similarly to cloning, stem cells, genetically modiﬁed organisms, and
gene therapy. Scientists, sociologists and bioethicists must be ready to
address these questions because new exploratory tools and therapies
cannot ﬁnd their place without being accepted at every level of the so-
ciety, i.e. individual patient, medical authorities, politics, and public
opinion. Even if the decision to be subjected to a particular therapy be-
longs to the patient, individual decisions are always inﬂuenced by ideas
that are conveyed at all levels of society, and medical authorities must
approve all therapies. In a recent paper, Petersen (2013) stated that
the rapid development of the life sciences and related technologies (in-
cluding neuroimaging) has underlined the limitations of bioethics3 per-
spectives and reasoning for addressing emergent normative questions.
The author pleads in favor of a normative sociology of bio-knowledge
that could beneﬁt from the principles of justice, beneﬁcence and
nonmaleﬁcence, as well as on the concept of human rights (Petersen,
2013). Even if some approaches are not biologically invasive, they can
be psychologically and philosophically invasive.
5.4. Conclusion
The technologies and ideas presented in this paper rejoin the state-
ment and conclusions of Schmidt and Campbell (2013), i.e. treatment
of eating disorders and obesity cannot remain ‘brainless’. A biomarker
approach combining genetic, neuroimaging, cognitive and other biolog-
ical measures will facilitate development of early effective precision
treatments (Insel, 2009; Insel et al., 2013), and serve individualized
prevention and medicine. Even though recent scientiﬁc discoveries
and innovative technology breakthrough pave the way to new medical
applications, our knowledge of the neuropsychological mechanisms
governing eating behavior and favoring the emergence of a disease is
still embryonic. Fundamental research in animal models and rigorous
bioethics approach are consequentlymandatory for a good translational
science in this ﬁeld.
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